Sham-operated animals
policy
taxonomy




compliance

Heart failure ; uk
CHF
air pollution ; heart failure
exercise ; cardiovascular system


HF



diuretic ; heart failure



reporting ; Cell ; Anand
doxorubicin
doctors ; blood transfusions
Heart failure ; bisphosphonates

Caspase ; gene expression ; heart failure
right heart failure ; pulmonary hypertension

exercise ; cardiovascular health
surgery ; heart transplant

Renal artery stenosis

HF ; pna
molecular mechanism



disease
dXA
FM
heart failure


environment

heart failure ; Latin america
HF


breathing ; heart beat

Heart rate


doctors
Nutrition ; heart failure
northwest united states



heart failure


Heart failure

clin

trans


internal ; cronbach
hypertension


Hazard ratios ; cox
monitoring devices

conditions
HR ; ea ; afterload burden
deaths ; strokes
frailty ; heart failure

exercise ; heart failure
RAS ; atherosclerosis
MicroRNAs ; heart failure
PSSS ; exercise
heart failure ; ejection fraction
Cardiology ; Bromodomain inhibition ; heart failure

heart failure ; cardiovascular death
cognitive function
correlated ; co
vasopressin ; congestive heart failure
Mitral stenosis ; medical ; heart failure
cardiac transplantation
medical conditions
frailty ;HF

LV fibrosis

dodson

CHF
heart failure
frailty


autonomic balance
HFpEF
Jehovah ; Witness ; anemia
ST2
Heart failure ; cognitive impairment
department of cardiology
follow-up
HF ; HF
exercise
markers ; hemostasis

Heart failure
HF

remote ischemic conditioning ; heart failure
Heart rate ; cardiac
cardiovascular disease
arrhythmia-related costs ; expenditures

pde2 ; HF
sts ; hm
physician
Medication ; sst2
Heart failure ; public health
albumin



HF
hospital
ET ; CHF
err ; molecular scaffolds ; heart pathology
spironolactone ; systolic heart failure
cox
Heart failure ;HF ; society
Epidemiology ; chronic heart failure ; bisoprolol
functional MS

VET ; aortic pressure curve
Cardiac symptoms
heart failure ;HF ;therapy
Trastuzumab-related cardiotoxicity ; breast cancer
physician
readmission ; metric
Tolvaptan ; vasopressin ; receptor antagonist
metric ; readmission metrics



black
etiology ; MR ; MS
Cardiac amyloidosis
ejection fraction ; bnp
HFpEF
beta blockade

Robot-assisted training ; heart failure

Chronic HF

Pigs ; antiarrhythmic medication
Heart rate ; arterial pressure
hgb level ; baseline ; HRQol
ejection ; outcomes
mortality
cardiac ; inflammatory biomarkers
HF ; cardiovascular
CHF ; intubated
mechanism ; circulatory arrest
chronic heart failure
outcomes ; heart failure
collected ; systolic dysfunction
HF
north america
acute heart failure


AHA ; esc
cps
circulation
ms ; surgery
toxicity ; systemic blood pressure
heart failure
HF
heart failure
HF


postoperatively ; multiorgan failure ; sepsis
Nordic walking ; heart failure
psychometric ; self-Care ; Heart Failure index
baseline ; heart failure
kidney injury
cox proportional hazards
endothelial function ; flow-mediated dilatation
heart failure ; cox
ms ; surgery ; echocardiography
Pharmacological ; acute heart failure

cardiac t2

heart failure
healthcare
biomarkers
TUg test





VO2max
exercise
Coronary angiography
dialysis
off-pump ; sternal sparing ; HeartMate II exchange
Hemodynamic ; Fontan
ESRD
survival ; Seattle ; Heart Failure model

HR ;HF
Heart failure ; left ventricular ejection
AI
acute heart failure

Treatment algorithms ; post-LVAD AI

exercise
anemia ; heart disease

QRs



public reporting
sinus rhythm ; AF
septal
health ; medicare

deficit index
physicians ;HF
heart failure ; cardiac rehabilitation
Race ; spironolactone ; heart failure
Myocardial infarction ; elicited ; Wistar rats

HF ; chromatin hyperacetylation

gLS ; cv ; AF
ms

medication ; hemodynamics
readmissions

systolic HF
postsystolic function
lVAD
Readmission ; hospital ; heart failure
income ; expenditure ; health per capita
outcome
aac ; cardiac hypertrophy
physical ; heart failure
keletal muscle abnormalities ; exercise capacity ; Fontan circulation
lead ; hypertension ; kidney failure
chronic kidney disease ;CK
change
anaerobic threshold ; heart failure
Mitral regurgitation ;HF
CHF ; unilateral renal DNx ; cardiac autonomic balance
renin-angiotensin-aldosterone system inhibitors ; heart failure
HR ; cardiac death
inflammation ; metabolism ; heart disease
Heart block ; pulmonary artery snared ; BiVP
heart lesions
ms
AF ; echocardiographic
Bioinformatic ; heart failure
cardiovascular events
diuretic ;HF
CAD ; systolic HF
PVf ; recovery ; PB
Nurses
diabetes ;EO-cFUs
blacks ; peak VO2 ; baseline
odds ratio ; accounting
change ; VET ; follow-up measurement
nitroxyl ; hno ; treatment of heart failure
physician ; urgent readmission ; heart failure
hf ; HFpEF

hospital ; readmission reduction ; congestive heart failure
economic ; accounting ; cost
HF
cRT ; dialysis-dependent patients
ms ;HF ; ms
compliance
ICU
Cardiac function ; pressure-volume conductance ; catheter system
RM
beta-blockers
CHF
sst2 ; BB therapy
evidence ;idiopathic dilated cardiomyopathy
Hypoalbuminemia ; heart failure
hypertensive LV dysfunction ; MR ; MS
etiologies
angiotensin receptor ; neprilysin inhibitor ; heart failure
western blot ; immunohistochemistry ; electron microscopy
diastolic dysfunction ; peripheral artery disease
unfolded protein response ; regulates ; cardiac sodium current ; systolic ; heart failure
cardiomyopathy
exercise intolerance ; chronic heart failure
biological ; mortality
exercise training ;ET ; endothelial function
cv ; death ; non-fatal stroke ; heart failure
AVd ; VVD ; free wall
Fat ; cachexia ; right ventricle ; heart failure
atrial fibrillation ;AF ; heart failure
ecb ; advanced heart failure therapy
heart transplantation ; left ventricular assist device
coronary disease ; heart failure
dialysis
right ventricular function ; body composition ; advanced heart failure
baseline ; eCGs ; electrocardiographers
left ventricular assist device ; right ventricular
incidence ; ESRD ; outpatients ;HF
wilcoxon ; signed-rank tests
subclinical atherosclerosis
connected ; heart failure
fm ; FM ; body weight ; CC
Renal artery stenosis ;RAS ; peripheral arterial disease
neurological ; cardiovascular
cardiac remodelling
proteome ; HDl ; shotgun ;LC-MS
heart rate
exercise ; exercise
rehospitalization
Cardiac cachexia ;cc ; body composition
ms ; mVA
TAC
DASh ; diet scores
heart failure
HF
southeastern Minnesota ;HF
branch block ; electrical activation
hHF ; dpp-4 ; inhibitors
hff
heart transplant ; ECCT
cRF
heart failure
Cardiac-resynchronization therapy ; heart failure
medications ; heart failure
miRNAs ; cardiac pathogenesis
heart failure ; care ; readmission
bem ; DT

coronary heart disease ; stroke ; heart failure
MLh
septal defects
iCD-HF
HF
hypotension

β-blocker ;BB ; sST2


extubated ; blood loss ; transfusion
malfunctioning HeartMate ; lVADs
Heart failure ;HF ; cardiovascular
ST2 ; plasma
veg inhibition ; cardiac function
biomarkers ; treatment ;HF
trastuzumab-related CHF
aerobic exercise
hospitals

transplants

Peak VO2
outcome

proteins
condition ; economic
financials
hypoalbuminemia ; lVAD ; surgery
holosystolic murmur ; heart
psoriasis ; atherosclerosis ; cardiovascular events ; Rotterdam
Coronary artery disease ;CAD ; systolic heart failure ;HF
HF ; hospital ; admissions ; transplant ; ventricular assist device
Heart failure ; rheumatoid arthritis ; tNF antagonist
HF ; haemodynamic ; neuronal stressors
lVAD
renal dysfunction ; post-transplant
germline ; DNA
Heart failure ; medical
Renal DNx ; circulating ; plasma ; CHF-inv rabbits

trastuzumab
np assessment ; ED
Cardiac hypertrophy ; energy metabolism
HF
blood work ; medication
s2 ; heart failure
Heart t2 ; heart failure ; arrhythmias
activated Caspase ; paced myocardium
heart failure ; health ; body composition
hh ; saxagliptin ; sitagliptin
HF
acr ; CMS
HDl-bound malondialdehyde ; HDl-induced
ED ; intubations ; congestive heart failure
CAD ; CAD


Survival ; hospital

anemia ; heart disease
heart failure
expression ; regulatory ;RI ;HF
heart failure ; ejection fraction
PET ; exercise ; CHF
nafat ; mir-25 ; transcription factor ; hand2 ; heart failure
Pediatric heart failure ;HF
eplerenone
renal denervation ; autonomic balance ; rabbits ; chronic heart failure
readmissions ; heart failure ; readmission quality
resistin ; ejection
right atrial myxoma ; pulmonary embolism ; right heart failure
Orthotopic heart transplantation ; oh ; heart failure
myxomas ; pulmonary arterial vasculature
baseline ; ecb ; cardiac transplant recipients
deficit index
Diet
evidence

iron
ED ; CHF
right ventricular contractile reserve ; pulmonary hypertension
Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
ST2 ; heart failure
baseline ; echocardiograms ; evidence of reverse remodeling
Titin hypophosphorylation ; myocardial
remote monitoring ; hospital discharge ; heart failure
bottleneck stent model ; chronic myocardial ischemia ; heart failure ; pigs
QT intervals ; SD ; QT intervals ;SD
LV ; filling pressure ; systolic HF
Medline ; EMBAse ; cinahl
RAS- ; β-blocker uptitration ;HFpEF
cps ; functional capacity ; peak VO2
pump failure ; driveline ; injury ; pump replacement
ischemic ; inflammatory abdominal problems ; MT
EH ;HFpEF
Framingham ; Heart study ;HF ; EF
Nicorandil ; doxorubicin
evidence-based therapies ; fes
evidence ; acp
diuretics ; heart failure ;HF
apoptosis ; canine model ; chronic heart failure ; tachycardia
lVAS
Cardiac ; Mammalian ;Mena ; heart failure
east ; rhythm control therapy ; cardiovascular complications ; AF
radiological ;HF
exercise ; coronary artery disease ;CAD
NOc ; outcome ; admission
HRQol ; exercise ; baseline ; hgb
skeletal muscle mass ; VO2
atrial fibrillation ; pacemaker
inpatient records ;HF
active
cardiac resynchronization therapy ; dialysis-dependent ; heart failure
pneumonia ; conditions
diastolic failure ; cardiomyopathic restriction ; flow
compliance ; exercise ; injections
pump exchanges ; pump ; thrombosis ; hemolysis
emergency cardiac catheterization ; extubated ; intermediate care
psychosocial factors ; exercise ; heart failure ;HF
medical ; heart failure ; Canadian Cardiovascular society
ees ; ventricular-arterial coupling ; SV

autonomic nervous system activity ; QTV
cRT
report model ; aRIC HF

change
degs ; osprey

world health organization ;HF ; LA
Medicare ; post-acute care transfer policy
cardiovascular
disease ; paediatric cardiac transplants
catheter ablation ; sinus rhythm
body mass index ; cRF ; treadmill exercise
myocardial tissue ; pKA
mortality predictors ; iCD-HF
myocardial fibrosis

Medicare

white
exercise ; diet

thics Rounds

heart failure
ED ; CHF ; intubation rates
bisoprolol ; mortality
health Buddy program ; telehealth
muscle-wasting syndrome ; acquired heart failure ; Fontan
Frailty ; health outcomes
heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure
rvpo ; BiVP ; RS synchrony
anemia ; heart disease ; american college of Physicians
cardiovascular death ;HF ; exercise training ; btes
exercise ; chronic heart failure ; high-density lipoprotein
Heart rate ; aortic blood flow ; doxorubicin

myocardial pde2 ; expression ; activity ; HF
anthracycline-induced cardiotoxicity
acute autonomic nervous system modulation ; QTV ; HF
BAT ; sympathetic outflow ; parasympathetic activity
end-stage renal disease ; outpatients ; systolic heart failure
Neurohormonal abnormalities ; pathophysiology ; congestive heart failure ; ghf
electrical predictors ; reverse remodeling ; cardiac resynchronization therapy
parasympathetic neurotransmission ; acetylcholinesterase inhibition
renal DNx ; cardiac autonomic balance ; CHF
Heart Failure ; pathophysiology ; medical
neurohormonal stimulation ; inflammation ; endothelial dysfunction
proof-of-principle cohort
activity ; i-mib ; myocardial washout
right ventricle ; RV ; cardiac function ; medical
costs ; heart failure ;HF
radiological ;HF
inhospital mortality ; bp
cardiopulmonary exercise ; heart failure
RV dysfunction ; weight loss ; body mass ratio
chromatin ; heart
HR reduction ; beta blockers ; exercise capacity ; hf
inhibition of protein kinase ; guanylate cyclase ; contractile
t test ; cis
cps ; functional capacity ; heart failure ;HF
HF
Mortality ; aCS
PSs ; btes ; exercise
ctnt ; NT-probNP ; HF
Jehovah ; Witness ; sickle cell ; disease ; anemia
miRNAs ; heart failure
physician ; conditions ; hospital
l-type ca2 ; currents ; Rad ; congestive heart failure
congestive heart failure ;CHf
health Buddy program ; ED
mri scanner ; baseline ; heart failure
defense mechanism ; cardiac stress ; β-AR drive
pulmonary artery ; pulmonary artery
dobutamine ; furosemide ; oxygen flow
LVEF ; long-term mortality
DASh ; diet ; heart failure ; women ; health
cps ; outcomes ; diabetes
anthracycline-treated breast cancer ; cardiotoxicity
circulationtory assist device
outcome change scores ; heart failure

exercise
transcatheter ; surgery
chemotherapy-induced heart failure ; breast cancer
insurance ; comorbidities
black race
chelation regimes ; heart iron
timed up and go test ; chronic organ failure
outcome ; heart failure
baseline ; ST2
pressure ulcers ; surgical
HF ; valve plasty ; ms ; mVA
PD ; refractory ; congestive heart failure ;CHf
NYHA
beta blockers ; heart failure
MT ; abdominal


futility ; monitoring board

Stress doppler echocardiography ; pulmonary hypertension
ejection fraction ; cardiac resynchronization therapy ; heart failure
co correlated ; septal wall ; AVd ; free wall ; VVD
LV ; strain rate ; echocardiography ; baseline
circulating ; outcome ; heart failure
etiologic ; acute RV failure ; left ventricular dysfunction
systolic ; diastolic ; mitral leaflet ; organic lesion
myocardial diastolic dysfunction ; collagen
ventricular ejection ; acute heart failure ; precapillary pulmonary hypertension
aortic valve insufficient ; left ventricular assist device
biventricular ; left heart ; twist ; porcine model ; right heart failure
cardiac nurses

UM ;VA-RT
heart failure
health
Czech republic
cardiac catheterization ; thrombotic obstruction ; right coronary artery
western blots ; monoclonal antibodies ; ser83 ; phosphorylation ;HF
hff ; dietary sodium restriction ; ventricular ; vascular
echocardiographic ; invasive hemodynamic
chronic heart failure ; ghf ; sympathetic tone ; autonomic imbalance
California ; office of statewide health planning and development ; Patient discharge
right atrium mass ; prolapse ; tricuspid valve ; stenotic physiology
preoperative serum albumin ; left ventricular assist device
outcome ; mwt
HF
CHF ; explants ; sham explants
herbal medicine ; dilated cardiomyopathy ; heart failure
implantable cardioverter-defibrillator deactivation

economic ; AF ; heart failure ; Québec
cardiac Mena deletion ; cardiac dysfunction ; conduction abnormalities ; hypertrophy
electromechanical delay ; dyssynchronous heart failure
trastuzumab ; cardiac comorbidities
bundle-branch block ;LBb ; abb
Font failure ; systolic ventricular function ; liver disease
cardiac filling pressures
protein levels ; western blot ; DNA fragmentation ; TUNEL ; autopsy
extracorporeal membrane oxygenation ; infarction-related refractory right heart failure
apoptosis ; pacing-induced dilated cardiomyopathy
Heart failure ; society ; cardiovascular diseases
Magnetically Levitated left Ventricular assistance system ; treatating Advanced HF
anticoagulation ; therapy ; heart disease
inotropic effect ; beta blockers ; heart failure
PAD ; ankle-brachial index
HR ; ivabradine ; TAC ; ea
NT-probNP ; circulation ; HF
energy metabolism ; heart failure ; hypertrophied heart
cancers ; health-care budget
baseline ; mechanical cardiac support ; renal function
systolic function
ecmo ; VAD ; ecmo+VAD
psoriasis ; smoked ; diastolic blood pressure ; body mass index
Treatment ; HRQol
ED ; New Jersey ; New York
cox models ; ST2
ms ; dynamic ; ms
transfusion ; mortality rates
TM ; sts
HF
Seattle ; Heart Failure model
MAD-corruption
neurological ; cardiovascular event-free rate
BETs ; TAC ; HF
chemical ; nitrite
aHF

HDl-induced NO production ; flow-mediated dilatation ; et
dopamine ; nesiritide strategy
cutoff level ; NT-probNP
heart failure ; protein kinase ; expression
cox regression ; cardiovascular events ; psoriasis
cp ;HF
change ; Paco2 ; cerebral blood flow ; perfusion ; carotid bodies
functional MS ; medical
HF ; epidemiology ; health service ; HF ; LA
heart failure ;HF
renal dysfunction ; mechanical cardiac
Heart failure ;HF
ventricular assist devices
hemoglobin ; health outcomes
cf

heart failure ; systolic heart failure
baseline ; rhythm-control ; rate-control
CF lVAD ; AI ; heart failure
evidence ; anemia ; heart disease
left ventricular dilatation
serum factors ; coagulability

PB ; HF ; primary oscillations ; central pattern generator
icc

HF
readmissions ; hospital ; pay-for-performance
echocardiography ; baseline
pro-adrenomedullin ;MR-proADm ; fm
New York Heart association ; walk
ms ; ring annuloplasty ; ischemic MR ; LV
exercise intolerance ; heart failure ; exercise
pathophysiology ; HF
ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
interleukin receptor ; ST2 ; beta-blocker therapy ; chronic heart failure
bp ; NT-probNP ; heart failure
Cardiorespiratory fitness ; body mass index ; heart failure ; cooperation center Longitudinal study
vasopressin receptor antagonist ; tolvaptan ; heart failure
diet ; exercise
hospitals
acute HF
administration ; trastuzumab-related CHF

cardiac death

hospital mortality
medical records
ejection fraction ;EF ; myocardial perfusion
Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
physical activity ; cardiovascular risk factors ; obesity ; diabetes mellitus ; hypertension ; hyperlipidaemia
Circulating ; natriuretic peptides ; plasma ; heart failure
heart failure ;HF ; left ventricular ejection fraction ;HFpEF
rial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
HF ; cardiac murmurs ; blood pressure
ATP ; XO-mediated ROS ; mitochondrial respiration ; contractile
cardiac angiogenesis ; coronary perfusion ; cardiac fibrosis
heart failure ; ventricular tachycardia
TUg test ; COPd ; CHF ; cRF
pressure-overload-induced heart failure
social mandate ; accountable ; outcomes
HF ; VT ; beat-to-beat QT intervals
biventricular dysfunction ; isolated HeartMate
procedure ; hemodynamically ; cp
heart failure ; long-term ventricular assist device
Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
isoproterenol ; cXL-1020 ; myocytes ; hearts
exercise intolerance ; chronic hff ; QOL
receptors ; adenylyl cyclase ; differential g-protein coupling
systolic HF ; etiology ; coronary angiography
mortality ; implantable cardiac defibrillator
jugular venous pressure ; peripheral oedema
Heart failure ;HF ; condition
rule ; CAD ; systolic HF
pump-exchange ; redo sternotomy ; cardiopulmonary bypass

baseline ; hgb ; exercise ; ktcc
medical ;HF ; HF ; ms ; mVA
ms ; medical ;HF ; ms ; dynamic ; medical
sonographic ; histological ; gastrointestinal
evidence ; parasympathetic function ;HF
exercise ; ambulatory HF
mechanical cardiac ; renal function ; heart failure
EH ; systolic blood pressure ; renal impairment ; hypertension
chronic myocardial ischemia ; heart failure
Morpholino-based knockdown ; nucleolin ; protein expression
hospital length ; rehospitalization
HFpEF
rule ; CAD ; CAD
diabetes mellitus ; cardiovascular disease ; baseline
HF-related cachexia ; RV function ; body composition
rule
ecmo ; egFR ; egFR
exercise ; haemodynamic ; pulmonary
general hospital ; cardiac specialty hospital ; south dakota
cognitive impairment
acs ; MT ; VAD
cvd ; psoriasis
energy substrate metabolism ; working hearts ; aac
evidence ;SCHf
Rotterdam ; psoriasis ; cardiovascular outcomes
HR ; tnf ; nbDMARD
Spironolactone ; hyperkalemia ; kidney injury
hereditary ; congenital abnormalities ; heart ; nontraumatic death
Fontan circulation ; skeletal muscle mass ; metabolic abnormalities
evidence-based practice
cardiovascular conditions ;HF
isolated HeartMate ; lVAD
albumin levels ; lVAD
mineralocortic receptor antagonists
right heart circulation ; right heart failure
MI ; HF
Fontan circulation ; sVR index ; cardiac index
isolated lVAD
health insurance ; health system ; u.s. ; Food and Drug administration
NT-probNP testing ; ED ; acute heart failure
blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic
bisphosphonate ; heart failure
cytoscape ; DAVID
Raf-MEK1/2-erk1/2
costs


patient
HF-induced remodeling ; emd
HF ; transition ; LV hypertrophy ; HF ; hh
heart failure ; ejection ; doppler echocardiography
natriuretic peptide levels
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
sympathetic ; parasympathetic activity ; HF
left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
heart transplantations ;LV assist device implantations ; heart failure
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
Xanthine oxidase inhibition ; ventricular systolic ; diastolic function ; cardiac
bem levels ;PAD ; bNP ;HF
heart failure ;HF ; Heart Failure ; retention Trial ;HARt
HF ; ejection fraction ;HFpEF ; hypertension
NYha
myocardial infarction ; anterior descending coronary artery occlusion
HFpEF ; breathlessness ; fatigue
immunodetection ; NT-probNP ; antibodies
Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; onset of heart failure
β-Blockade ; cardiac angiogenesis ; heart failure ; veg
myocardial ischemic events ; cardiac resynchronization therapy
report ; aortic valve surgery ; post-LVAD
unloading ; heart ; isolated HR reduction ; systolic heart failure
spironolactone ; systolic heart failure
Heart failure ; medicine ; atheromatous coronary disease
Heart failure ; HF ; Latin america ;la ; health service ; HF
rehospitalization ; medicare
HF ; cRT ;hazard ratio
palliative care
HFpEF ; medical ; physical
oxidative stress ; GTPase Rac1 ; activity ; hearts ; ANS
resistin ; circulating mediator of insulin resistance ; monocytes ; inflammatory
cardiovascular death ; urgent cardiac transplant
medications ; outpatients ; heart failure ; NCd PINnaCLE
beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure
CHF ; emergency department ; ed ; intubated
LCx ; LAD ; two-vessel disease
RV dysfunction ; weight loss ; body composition ;HF
congestive heart failure
mitochondrial ; reversal ; sarcomeric
art failure ; Emergency department ; ed ; ED
degs ; non-ischemic ; ischemic heart failure
pp ; acr ; CMS
gut ; inflammation ; heart failure ; heart failure
heart failure ; ejection fraction
Intravenous iron ; heart failure ; iron
robot-assisted gait therapy ; Lokomat ; heart failure
conditions ; heart failure

readmission rate


psoriasis ;UV
NT-probNP ; HF ; immunoprecipitation ; mass spectrometric
Chromatin-associated proteins ; chromatin ; DNA ; gene expression profile
diastolic dysfunction ; hff
right ventricle overload ; leads ; stroke ; ventricular ejection time ; lVET
β-Adrenergic receptor blockade ; heart failure ;HF
PD ;HF
transoesophageal echocardiography ; thrombosis ; migration
hand ; heart muscle cells ; pathological hypertrophy
follow-up ; death ; readmission ; heart failure
dialysis ; echocardiographic
zf1 ; heart failure ; ejection fraction
ambulatory HF ; ventricular ejection
QT variability ; qv ; Qv ; cardiac death
cross-talk ; heart ; adipose tissue ; cachectic heart failure ; body
arterial tonometry ; VET ; precapillary PH ; heart failure
heart magnetic resonance imaging ; chelation ; compliance ; heart disease ; thalassaemia
PARADIGm-HF ; chronic heart failure ; Chronic heart failure ; cardiology
abm ; implantable cardioverter-defibrillator deactivation
New Zealand ; white rabbits ; renal DNx ; CHF
HDl function ; et ; CHF-NYHA-IIIb ; HDl function
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
lVET ; death ; ICU
exercise ; hemodynamic
Cardiac failure ; type 2 diabetes ; molecular mechanism ; diabetes ; heart failure
pulmonary hypertension ;PH ; heart failure
Beta-blocker
CHF ; activated neurohormonal systems
heart rate ; renal function ; spironolactone
evidence ; microRNAs ;miRNAs ; heart failure
mri ; tidal respiration ; myocardial t1 ; swine ; heart failure
medical ;HF
miRNAs ; cardiac remodeling ; heart failure
septal ; likelihood ratio
cardiovascular disease ; dRS

hospital ; AMI ; mortality rates

frailty ; heart failure ;HF
heart failure ; bisphosphonates
beta-blocker therapy
psoriasis ; cardiovascular disease ; cvd
pde2 ; cardiomyocytes ; norepinephrine-induced hypertrophic
readmissions
cardiovascular disease ; baseline
costs
advantage ; power ; technology
Rhythm control therapy
RAS-blocker ; hff ;HFpEF
LV ; diastolic dysfunction ; filling pressures ; doppler echocardiography
Hemoglobin ; exercise ; health ; heart failure ;HF-ACtion
cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
myocardial collagen ; titin isoforms ; phosphorylation
Cardiac magnetic resonance ; outcome ; heart failure ; ejection fraction
systems proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cellular plasticity ; cardiomyocytes
cardiotoxicity ; doxorubicin ; anti-neoplastic agent ; cancers
heart failure ; left ventricular ;LV ; ejection fraction
Fontan ;SAF ; catheterization
natriuretic peptides
AlphaLISa ; immunoassays ; NT-probNP
HF ; rheumatoid arthritis ;RA
financial ; HF ; CMS ; conditions
implantable cardioverter-defibrillator deactivation
sinus rhythm ; antiplatelet agents ; anticoagulants
death ; biological
β-Blocker-induction ; cardiac angiogenesis ; therapy ; cardiac function
physician ; index admission
expression ; Bax ; bcl-2 ; proteins
GDm ; GDm ; BAT
heart failure ; ccnKA sNP
alendronate ; alendronate ; heart failure
transduction pathways
baseline
Plasma samples ;HF
regulation ; feeding ; nutritional ; anti-inflammatory ; CHF
diastolic dysfunction
acs ; oHT ; bridged ; transplant ; MT ;VAD
RAS- ; β-blocker
drugs ;HF ; ejection fraction ;HFrEF
Kansas City ; Cardiomyopathy ; heart failure ; ejection fraction
heart failure ; ejection fraction ; hff
bem ; NT-probNP ; coronary artery disease ;CAD
functional mitral stenosis ; ms ; ring annuloplasty ; ischemic mitral regurgitation
heart failure-related hospitalization ; left ventricular ejection
refractory congestive heart failure ; peritoneal dialysis
heart failure ; elevated left atrial pressure
zSF1 ; obese ; zSF1 ; diabetic
doppler imaging ; left ventricular filling pressure ; systolic heart failure
Heart failure ; ejection fraction ;HFpEF ; cardiovascular
MT ; VAD ; acs
LV ; diastolic dysfunction ; combination ; figure ; mechanism ; hf
Mammalian enabled ;Mena ; regulator ; cytoskeletal actin dynamics ; heart failure ;HF
Gastrointestinal bleeding ; ventricular assist devices
ARNI ; inhibitors ;angiotensin-receptor neprilysin inhibitors
fes ; ejection fraction ;HFpEF
myxomas ; cardiac benign tumors
nicorandil ; cytotoxic effect ; doxorubicin ; Ehrlich carcinoma
ambulatory iCD
Heart failure ; ejection fraction ; hff ; cardiovascular reserve
Renal denervation ; dnx ; CHF
heart failure
hyperkalemia ; kidney injury ; spironolactone
myocardial pde2 ; intracellular antiadrenergic therapeutic strategy ;HF
carotid ; intima-media thickness ; psoriasis
coronary occlusion ; stent occlusion
HF
combination ; exercise ; diet ; peak VO2 ;joint effect
spironolactone
RV dysfunction ; cardiac cachexia
ecg ; cRT
mechanical dyssynchrony ; cRT
pharmacologic treatment ; pharmacologic
iea ; heart failure ;HF ; cRT-d
chronic heart failure ; Hungary
breast cancer ; trastuzumb-related CHF
remote monitoring ;RM ; heart failure
Process
NT-probNP
PVf ; PB ; recovery period ; BP
transfusions ; heart disease
exercise
sst2 ; low-dose BB ; cardiovascular event rate
ecb
peak aerobic capacity ; left-hand grip ; body weight ; waist circumference
myocardial loss ; irr1 ; irr2 ; heart failure ; p38alpha MAPK ; insulin resistance
heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
ICU ; admission ; precapillary PH ; heart failure
Renal dysfunction ; cardiovascular events ; primary isolated cab
baseline ; isoprenaline infusion ; SDQT ; hNorm ; HF
heart failure ; ejection fraction ; myocardial infarction
coronary artery disease ; systolic heart failure ; etiology
ea ; arterial compliance ; TAC ; end-systolic elastance ; ees ; baseline
aldosterone antagonist ; heart failure
Genetic ; anthracycline-related congestive heart failure ; haematopoetic cell transplantation
cardiovascular risk factors ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ;HFpEF
Renal dysfunction ; myocardial infarction ; coronary artery bypass grafting ; cab
biventricular ; HeartMate ; lVAD ; centriMag RVAD
angiogenesis ; post-myocardial infarction heart ; heart failure
pde2 ; hearts ; β-AR
medical ;HF ; hypertension ; vasodilators ; diuretics
egf ; diuretics ; hypertension ; ESRD
heart failure
np levels ; ED ; outpatient settings ; acute heart failure
EO-cFUs ;hazard ratio
trastuzumab ; CHF ; nontrastuzumab
heart disease
HR ; beta-blocker therapy
acute heart failure ; HF ; heart failure ;HF
psoriasis ; disease ; atherosclerosis ; cardiovascular ; psoriasis
HF ; emd ; dyssynchronous failing heart
Pyridostigmine ; vascular endothelial growth factor ; left ventricle ; myocardial angiogenesis
idiopathic dilated cardiomyopathy
cardiac growth ; disease recapitulates ; chromatin remodeling
CHF ; international classification of Diseases
MEDline ; EMBAse ; cochrane ; trial ; technical
egf ; VAD ; ecmo ; VAD ; ecmo
baseline ; ea ; TAC ; HR ; ees
ERC ; epicatechin ; muscle function
Robot-assisted gait therapy ; Lokomat ; system ; heart failure
baseline ; cf ; HF ; mortality risk ; HF
RV dysfunction ; body mass index ; fat mass index ; cachexia
HF ;HF
myocardium ; expression ; pKA ; downstream
technology ; health outcomes ; Medicare
hff
exercise ; cardiac disease ; heart failure
HDl function ; CHF ; HDl-mediated vascular
HF ; HF ; mortality
physician ;HF cps
lVAS
biomedical ; nonprescribing
black race ;HF ; cardiovascular mortality
dopamine ; nesiritide

Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic ; general anaesthesia
isoelectric ; RIα ; ser77 ; ser83 ; vivo phosphorylation
baseline ; NT-probNP ; MR-proanp ; MR-proadm
tnf ; HF ; admissions ; nbDMARDs ; RA
epidemiology ; myocardial infarction ; m ; heart failure ;HF
Heart rate reduction ; exercise ; heart failure ; ejection fraction ; beta-blocker hypo-response
HeartMate ; biventricular ; HeartMate II
conditions
mADIt-pact ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
admission ; serum levels ; brain natriuretic peptide ; bem ; creatinine ; natremia
RAS ; hypertension ; nephropathy ; congestive heart failure
MS ; valve plasty ; MR ; LV ; disease
elastic na2Bus ; PEvk
end stage heart failure ; Heart failure ; public health ; europe ; northamerica
Nicorandil ; mitochondrial dysfunction ; doxorubicin-induced heart failure ; mechanism of cardioprotection
HeartMate ; left ventricular assist system ; lVAS ; advanced heart failure
cXL-1020 ; inactive ; cXL-1051
arterial elastance ; ea ; pulsatile afterload ; heart ; pressure
pharmacologic ; acute HF ; chronic HF
proteomics ; chromatin-associated proteins ; detergent
heart failure ; mechanical ; Cardiology- cardiovascular Surgery ; report ; Heart failure
collect ; heart failure ; implantable cardioverter-defibrillator
self-Care ; Heart Failure index ;SCHf ; psychometric profile
atrial fibrillation ; carvedilol ; metoprolol
SDQT ; rr intervals ;SDr ; qv ; heart rate
health care providers ; gastrointestinal bleeding
readmission rate ; heart failure
Logistic ; outcome ; secondary outcome ; death
egf ; VAD ; ecmo ; VAD ; renal function
ucs ; eseptal ;emean ;septal ; resynchronization
physical ; mortality ;HF ; noncardiologist
LV ; ejection fraction ; PCw
diuretics ;HF-related
readmission rate ; congestive heart failure ; united states
IVc occlusion ; co correlated ; twist ; apical rotation ; RS ; RS synchrony
CHF ; ED ; CHF ; intubated
emergency department ; acute heart failure ; Collins
zebrafish ; Nucleolin ; genomic reprogramming ; disease
evidence
gls ; cv
sst2 ;low-dose BB ; sst2 ; high-dose BB
cardiac events
ejection fraction
incidence ;HF ;AMI
exercise ; diet ; exercise ; diet
mortality
nurses
HF ; drug ; PAf ; biosynthetic enzymes ; lyso-paf-AT
cardiac magnetic resonance imaging ; hemodynamic assessments ; baseline
HF ; ejection fraction ; pEF
mouse ;HF ; hh ; salt loading ; uninephrectomy ; ANG II infusion
Dual RAS ; neprilysin inhibition ; change ; chronic heart failure ; systolic dysfunction
administration ; gadolinium-chelate contrast
Medicare ; inpatient ;HF ; admissions ; acute care hospitals ; united states
idiopathic dilated cardiomyopathy ; Tuscany
HFpEF ; HF ; EF
report ; DAPc ;dystrophin-associated protein complex ; sarcomeric ; baseline
low-dose dopamine ; low-dose nesiritide ; acute heart failure ; renal dysfunction ; ROse ; acute heart failure
catheter ablation ; atrial fibrillation ; heart failure ; ejection fraction
ecg ; accessory pathways ; ion channelopathies ; cardiomyopathy
heart failure ;HF ; inpatient ; outpatient
HF rats ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
evidence ; intravenous iron ; exercise ; heart failure
erythropoiesis-stimulating agents ; anemia ; heart disease
bet ; bromodomain-containing protein ;BR4 ; cardiac tissues
costs ; Québec ; health insurance board ; costs ; Ontario case costing Initiative
report ; mitral valve plasty ; mitral regurgitation
carvedilol ; metoprolol ; heart failure
HF ;heart failure ; t2d ;Type 2 diabetes ; Skm ;skeletal muscle
public health ; air pollution ; cardiovascular health ; lead
evidence ; molecular biomarkers ; pathophysiology ; chronic HF
cardiopulmonary exercise ; muscular strength ; peak quadriceps force
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat metabolic risk
NT-probNP ; antibodies ; nonglycosylated
university of Connecticut ; Heart Failure Center ; cardiologist ; heart failure
baseline ; serum creatinine ; serum potassium
PD ; weight loss ; diuretic ; peripheral edema
echocardiographic predictors ; cardiac resynchronization therapy ; cvt
HeartMate ; lVAD ; centriMag RVAD
HF ; ejection fraction ;EF
anemia ; chronic heart failure ;HF
Hum-retn mice ; cardiac mRNA ; inflammatory ; cell adhesion ; Retn
chromatin ; heart failure ; mechanisms ; chromatin
HFpEF ; ccq ; health
nbDMARD ; tnf ; antagonist ; baseline
exercise ; heart failure
AF ablation
heart failure ; mechanical cardiac
Chronic heart failure ; transforming growth factor
RV failure ; intrinsic left ventricular dysfunction
readmission rate
admissions ; emergency department ; ed
evidence ; economic models ; lVAD
echocardiographic score ; cRT
ejection fraction
If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; ejection fraction
Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
nutritional abnormalities ; CHF
vena cava ; icc ; snared
doxorubicin ; ip ; induction of serum resistin ; Hum-retn mice
costs ; physicians
direct observation ; rheumatic ; MS ; mVA


HF ; pyridostigmine ; stroke ; ejection fraction ; cardiac output ; contractility
myosin binding protein-c phosphorylation ; ser23/24 ; troponin I phosphorylation ; HF
aldosterone receptor antagonists ; symptomatic systolic heart failure
uPR ; protein kinase ; er kinase ;perk ; calreticulin ; chop ; HF
hf ; exercise ; HR ; beta-blocker therapy
electrical ; natriuretic peptide ; inflammatory markers
cox hazard models ; ESRD ; corruption ; ESRD ; death ; ESRD
RCs
heart failure ; heart failure ; cardsiology
heart failure ;HF ; cardiopulmonary exercise test ; anaerobic threshold
renal dysfunction ; stroke ; myocardial infarction ; heart failure ; cab
XO inhibition ; cardiomyocyte bioenergetics ; LV ; chronic aCF
carvedilol ; thromboembolic events ; heart failure ; β-receptor haplotype
pyridostigmine ; administration ; methylatropine ; propranolol ; cardiac sympathovagal balance
baseline ; PAf ; activity ; metabolic enzymes ; heart failure
trastuzumab ; cardiotoxicity ; congestive heart failure ; ghf
Phosphodiesterase-2 ; hearts ; blunts ; beta-adrenergic responses ; cardiomyocytes
lipolysis ; energy expenditure ; natriuretic peptides ;NPs ;cc
cox ; health ; health status ; hazard ratios
east ; rhythm control therapy ; AF ; cardiovascular complications ; AF
hearts ; Mena ; cardiac injury ; Mena ; HF pathophysiology
scn5a ; uPR ; downregulation ; cardiac genes ; HF
gls ; index beat ; cv ; cox
VAD ; ecmo ; VAD ; ecmo
tpse ; PASp ; tpse
right ventricular ; RV ; left ventricular assist device ; lVAD
albumin levels ; nutrition ; inflammation ; hepatic function ; lVAD
ST2 ; discrimination
post-hCT CHF ; hCT ; City of Hope
non-ischemic ; ischemic heart failure ; biomarkers ; heart failure
CHF ; infarcted animals ; left ventricle ; end-diastolic pressure ; hg
health ;HF
Peak oxygen consumption ; oxygen pulse
dialysis-dependent ;HF ; cRT
RV ; pathophysiologic mechanisms ; RV dysfunction
cardiac deaths ; atherosclerotic CAD
Ambient air pollution ; cardiovascular health ; acute myocardial infarction
economic ; NHs ; behavioural-change ; chronic disease ; exercise
non-fatal stroke ; heart failure
molecular dysfunction ; chronic HF
ccq ; Kaplan-meier curves
cRT-d ; IE ; defibrillator-only therapy
HR dynamics ; HR ; risk

obesity ; diabetes mellitus ; metabolic risk factors ; heart failure ; ejection fraction
atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD
AMI ; heart failure ; kidney infection ;UTI
cardiopulmonary exercise ; echocardiographic ; myocardial function ; left ventricular filling ; exercise
coronary revascularization ; hemodynamically ; intensive care unit ;ICU
speckle tracking ; echocardiography ; STE ; BiVP ; right ventricular pressure overload ;RVpo
pathophysiologic mechanism ; renal underperfusion ; renin- angiotensin-aldosterone pathway
Olmsted County ; Minnesota ; MI ; HF
proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
neurohumoral blockers ;HF ; co-morbidity
hawt ; hawt ;AMI
rule ; CAD ; CAD
vascular endothelial growth factor ;VEg ; transition ; compensatory hypertrophy ; cardiac failure
left ventricular ejection fraction ; heart failure ; Heart failure ; israel
collected ; medical ;HF
icc ; multicenter Automatic Defibrillator Implantation ; Trial-Cardiac resynchronization Therapy
testosterone therapy ; exercise ; heart failure ; testosterone
health Buddy program ; admissions ; chronic obstructive pulmonary disease ; congestive heart failure
RAS ; doppler ultrasonography ; tomographic angiography ; magnetic resonance angiography
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
echocardiographic ; LV ; reverse remodeling
perk inhibition ; full-length scn5a ; kv4.3 ; mRNA ; na- channel mRNA splice
bottleneck stent ; myocardial infarction ; antiplatelet medication
bem ; HF ; bem
Trastuzumab ; CHF ; nontrastuzumab ;hazard ratio
Rad variant ; congestive heart failure
salt loading ; uninephrectomy ; ANG II infusion ; cardiac function ;HF
Mena ; expression ; HF ; Mena ; cardiac pathophysiology
LVf ; long-term mortality ; hospitalization ; HF
Fontan failure ; circulatory ; hemodynamic ; portal hypertension ; cardiac output
HF ;AMI ; hazard ratio
systolic heart failure ; spironolactone
uPR ; mRNA splice ; cardiac ; na+ current ; HF
diuretic ; neurohormonal activation
BETs ; transcriptional pause release ; transcription ; pathological stress
evidence ; lVAD ; transplantation ; budget
LVEF ; LVEF
apoptosis ; pathogenesis ; heart failure
regulation ; programmed cell death ; degs
ecg ; atherosclerotic CAD ; cardiac death
HR reduction
ANS mice ; LV ; lung
atrial fibrillation ; atrial fibrillation ; Stroke prevention
heart failure ;HF
MS ; valve plasty ; annular size reduction ; MR ; LV
idiopathic dilated cardiomyopathy
right ventricular ;RV ; body composition ; advanced heart failure ;HF
american college of Cardiology ;American Heart association ;RAS ;RAS
arn ; cardiovascular mortality ; heart failure
peak work rate ; peak quadriceps force
implantable cardioverter-defibrillator deactivation ; heart failure
EO-s ; cd34 ; vegFR2 ; cells ; nondiabetic
report ; MS ; valve plasty ; MR ; LV
exercise ; anaerobic metabolism ; peak respiratory
exercise training ;HF ; exercise ; training therapy
myocardial dd ; muscle strip ; titin hypophosphorylation
np measurement ; nps
etiology
readmission rates
financial ; evidence ; intestinal morphology ; permeability ; absorption function ; CHF
expression ; cardiac hypertrophy ; Nucleolin

Blood pressure ; arm cuff ; stroke volume ; ejection fraction ; end-diastolic ; echocardiography
Kansas City ; Cardiomyopathy Questionnaire ; kv ; HF ; hpEF
biventricular ; hybrid ; HeartMate ; lVAD ; centriMag ; right ventricular assist device ; VAD
Tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure relationship ; heart failure ; right ventricular contractil
fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue ; histologic
bem ; DT ; bt
expenditure ; health per capita ; income per capita ; HF ; LA
borderline
blood pressure ; lipid-lowering therapy ; smoking ; foundation ;RAS
SDwt ; HFVT ; hNorm ; fixed-rate atrial
costs ; cost-effective
AF ; pharmaceuticals ; hff
IEs ; cRT-d ; heart failure
bem ; inhospital mortality
diffuse myocardial changes ; heart failure ; contrast agent
Implantable cardioverter-defibrillators ;ICds ; cardiac resynchronization therapy ; cvt
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal function
Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; heart failure
NT-probNP levels ; dyspnea ; left ventricular dysfunction ; admission ; ED
contractile ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
Circulating progenitor cells ; cps ; endothelial repair ; cardiovascular diseases
HF-ACtion cohort ; baseline ; hgb ; baseline ; HRQol ; kvq
pathological ; heart ; cardiac hypertrophy ; HF ; fibrosis ; inflammation
snp ; Ka renal chloride channel gene ; cnp
HFpEF ; echo-doppler cardiography ; haemodynamic assessment
LV ; diastolic ; XO inhibition ; heart failure
RAS- ; β-blocker ; uptitrations ; hFrEF ; HFpEF
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
DASh ; diet ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
Yorkshire swine ; pacemakers ; beats ; induce heart failure
echocardiographic score ; reverse remodeling ; cRT
isolated heart rate ;HR ; ivabradine ; afterload ; systolic heart failure
biomedical ; CHm ; biomedical treatment ; dm ; heart failure
Cardiovascular ; Renal Atherosclerotic Lesions ; coRAL ; stenting ;RAS
centrifugal flow pump ; magneticically levitated rotor ; blood-flow paths ; artificial pulse
mitochondrial complex ; activity ; post-aac ; ratio ; phosphocreatine ; ATP
Mediterranean and Dietary apps ; stop Hypertension ;DASh ; diet scores ; postmenopausal women ;HF
heart failure ; ejection fraction
mortality ; heart failure ;HF ; implantable cardioverter defibrillators ;ICds
physical ; outcomes ; health ; HF
frail ; intermediate frail
eplerenone ;HF-ref ; inducing hyperkalemia ; wRF
emergency department ; acute heart failure ; aHF
RM ; heart failure
lb ; implantable cardioverter defibrillator-cRT ; primary outcome
standard error of measurement ; md ; change
embryonic gene ; pathological heart disease ; transcription factors
hff ; outcome-monitoring ; cardiac
sst2 ;low-dose ; sst2 ; high-dose ; intermediate odds ratios ; cardiovascular events
skeletal muscle sarcomere ; heart failure ; type 2 diabetes ; epicatechin-rich cocoa
QRs morphology ; cardiac resynchronization therapy ; cvt
exercise-induced PASp ; hg ; PASp
heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; medical ; heart failure
np levels
readmissions ; costs
lb ; QRs ; implantable cardioverter defibrillator-cRT
echocardiography ; cardiac diameters ; cardiac function
electronic ; MEDline ;EMBAse ; PsycINFO

medical
ST2 ; cardioprotective ; myocardium ; heart failure ;HF
systolic HF ; cXL-1020 ; left ; right heart filling ; systemic vascular resistance ; cardiac ; stroke
outcome ; cardiovascular death ; stroke ; heart failure ; myocardial infarction
Cardiac-resynchronization therapy ; cvt ; chronic systolic heart failure
perk activation ; scn5a ; kv4.3 ; mRNAs ; transient receptor potential cation ; m7 ; tlp7 ; mRNA
implantable cardioverter-defibrillator ; Heart function Clinic ; university health network ; toronto ; Canada
exercise-induced PASp ; pulmonary hypertension ; ventricular contractile reserve
MI ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
outpatient assessments ; heart failure ; readmissions
antiplatelet agents ; anticoagulants ; vascular diseases
Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sVR ; cardiac index
myofiber dynamics ; myofiber ; emd ; dyssynchronous HF
ankle-brachial index ; pulse-wave velocity ; coronary artery calcium
unfolded protein response ; ucp ; scn5a ; electric remodeling ; HF
intermacs ; internal activity Registry for mechanically assistance Circulatory support
international right Heart foundation working group ; syndrome ; right heart failure
cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; ac
HF ; HF ; epidemiology ; SH ; rheumatic fever
caloric restriction ;diet ; aerobic exercise training ;exercise ; exercise capacity ; QOL ; hff
chronic heart failure ;HF ; hemodynamic disorder ; syndrome
medications ; heart failure ; ejection fraction
HFpEF ; diastolic filling ; heart rate
cardiac myocyte-specific Mena overexpression ; tgtetMena ; cardiac pathology
allopurinol ; contractile ; XO-mediated ROS ; myofilament
rate ratio ; treatment ; comorbidities
AF ; heart failure ; financial burden
rehospitalization ; Medicare ; claims ; Medicare ; post-acute care transfer policy
heart failure ; refill ; compliance ; etidronate ; alendronate
metabolic exercise ; cardiac ; kidney index
physical ; cf ; HF mortality
et ; HDl-mediated protective effects ; molecular pathways ; chronic heart failure ;CHf
physicians ; advanced heart failure
isolated heart transplant ; ecb
body ; FM ; fm ;cc

ventricular ejection fraction ; ventricular diastolic end diameter
outcomes ; concentric left ventricular hypertrophy ; heart failure ; ejection fraction
left ventricular ejection fraction ; heart failure ; ejection fraction ; hpEF
β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; heart
baseline ; hg ; correlated ; baseline ; ghg ; exercise ; HRQol
mechanisms ; bone morphogenetic protein ; expression ; rRNA transcription ; heterochromatic chromatin
low-dose dopamine ; nesiritide ; renal function
actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
elevated resistin ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
extracellular matrix ; left ventricular biopsies ; tissueFAXs ; technology
systolic HF ; Danish Heart Failure ; erd ; Danish Registry on Dialysis
left ventricular assist devices ; lVADs ; heart failure ; pump dysfunction ; pump replacement
bn ; diastolic dysfunction
hART ;HFpEF ; HF ; ejection fraction ;HFrEF
imaging techniques ; systolic function ;HFpEF ; axis function ; exercise
HF ; odds ratio ; mortality ; hazard ratio
AAs ;HF ; hyperkalemia ; hypokalemia ; spironolactone
receptors ; g-protein-coupled receptor kinase-2 ; desensitization
NT-probNP ; glycosylated
scn5a ; angII ; hypoxia ; expression ; induced ; uPR ; downregulation
ST2 ; outcomes ; amino-terminal ; natriuretic peptide
sst2 ; high-dose BB ; sst2 ; low-dose BB ; cardiovascular
anemia ; iron deficiency ; MEDline ; cochrane Library
neurohormones ; adipokines ; body composition ;cc ; fat free mass ; fm ; fat mass ;FM
cardiac plasma membrane levels ; s1p1 ; β1AR overstimulation ; heart failure
Sprague-Dawley ; sham ; acf ; allopurinol
myocardial collagen ; myocardial delayed enhancement imaging
saxagliptin ; sitagliptin
magnetically levitated lVAS ; Seattle ; Heart Failure
change
kv ; HFpEF ; ronbach
implantable cardioverter defibrillator-CRT ; non-LBb
principal mechanisms
alendronate ; etidronate ; raloxifene-treated
Chemotherapy ; trastuzumab ; CHF ; international classification of Diseases ; healthcare
heart failure ;HF ;HF ; left ventricular ejection fraction ;LVEF
tachypacing-induced HF ; cXL-1020 ; contractility ; end-systolic elastance ; venoarterial dilation
cRT ; hazard ratio
MT ; operation
cox ; transplantation ; LV assist device ; heart failure
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase activity
correlation coefficient ; icc ; kappa coefficient ; change ; mdc
Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic drugs
race ; exercise training ; chronic heart failure ; Heart Failure ; exercise ;HF-ACtion
biomedical ; CHm ; biomedical treatment ; dm ; heart failure ; PubMed
national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; cab
biventricular pacing ; biVP ; cardiac output ; co ; cardiac surgery
New York Heart association ;NYha ; chronic heart failure ; ejection fraction
AlphaLISa ; immunoassays ; antibodies ; NT-probNP
creatinine ; bp ; furosemide ; oxygen flow ; dobutamine ; norepinephrine
expression ; regulation ; Rad Q66p ; RGK protein
Myocyte hypertrophy ; heart failure ; gene expression ; DNA
Catheter ablation ; AF ; hff ; left ventricular ; ejection fraction
Cardiology ; national Cardiovascular Disease Registry ; practice
readmission rate ; congestive heart failure ; midwestern state ; South dakota
ms ; medical ; all-cause mortality ; heart failure
induced myocardial infarction ; heart failure ; bisoprolol
transitions ; health
CHF ; cardiac explant ; c-Kit ; mechanisms ; regulation
tachycardia ; intravenous atropine ; cardiac vagal tone ; CHF-DNx ; CHF-inv
cardiomyocytes ; mechanical ; humoral ; myocardium ; conditions
biological ; medical records
BB therapy ; sst2 measurement ; chronic heart failure ; BB
erd ; systolic HF ; egf
pip relationship ; length-force relationship ; RV function ; LV
wind assay ; apoptotic cells ; TUel-positive cells
hno donor ; myocardial function ; evidence ; HF
erus ; explanted
Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF
heart failure ; ejection fraction
report ; hno donor ; cvm-1020) ; isolated myoctyes ; intact hearts ; heart failure ;HF
physical ; bem ; heart rate ; lying ; standing ; blood pressure ; auscultation ; valvular disease ; pulmonary congestion
myocardial extracellular matrix ; cardiac magnetic resonance ; pathobiology ;pathophysiology
aldosterone antagonist therapy ; advanced heart failure ; post-myocardial infarction ; heart failure ; ejection
Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin ; cardiotoxicity
heart failure ; left ventricular ejection ; spironolactone ; Kaiser Permanente Northern California
SDQT ;HFv ; hNorm ; β-adrenoceptor blockade ; esmolol
heart failure ; chamber programme ; candesartan ; Heart Failure assessment ; Mortality and Morbidity
heart failure ; ejection fraction ; hff ; heart failure ; overweight
Renal dysfunction ; heart failure ;HF ; renal disease ; erd
echocardiographic score ; LV ; reverse remodeling ; LV ; end-systolic volume
Peripheral artery disease ;PAD ; heart failure ;HF ;HF ; PAD
readmission rates ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; Fontan circulation
preoperative renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; isolated coronary artery bypass grafting
asymptomatic ; Fontan ; PF ; catheterization
ms ; dynamic ; ms
ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
Lancet ; Anoop Shah ; air pollution ; heart failure
anemia ; HF ; health-related quality of life ;HRQol ; HF
cell therapy ; chronic heart failure ; ghf ; disease
mri-based ; dyssynchronous nonfailing ;HF ; canine electromechanics
american college of Physicians ; acp ; evidence ; anemia ; iron deficiency ; heart disease
exercise ; cell senescence ; active ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia

chronic heart failure ;HF ; exercise
histological ; capillary ; coronary perfusion ; ad-fraud
physician ; mortality ; cardiologists
shuttle walk test ; body mass ; hand grip strength ; baseline
power testing ; np ; ED
Troponin t ; natriuretic peptide ; heart failure ; atherosclerosis
tachycardic response ; methylatropine ; vagal tone ; bradycardic response ; propranolol
acute RV failure ; chronic pulmonary arterial hypertension ;PAh ; acute pulmonary embolism
cardiac resynchronization therapy ; cvt ; heart failure ;HF ; QRs ; ejection fraction ;EF
flow reserve ; positron emission tomography ; ischemia ; bottleneck stenting ; left ventricle ; LAD
mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation
cox regression ; spironolactone ; death ; hyperkalemia ; kidney injury
outcomes ; cardiovascular mortality ;HF ; cox models ; exercise
cardiac transplant ; ecb ; transplant pool ; transplant
exercise ; medical Therapies ; Cardiac function ; Breath ; Lung congestion
septum ;systolic ; LV ; posterior wall thickness ; LV ; internal diameter ; metoprolol
hff ; caloric restriction ; aerobic exercise ; peak VO2
economic ; Heart failure ; cost-efficient ; disease management ; heart failure
HF ; HF ; HFpEF
BAT ; natriuretic peptide ; HF
HR variability ; AMI ; CHF ;LV
neprilysin inhibitors ; natriuretic peptide system ; breakdown ; atrial natriuretic peptide ; natriuretic peptide
postoperative ; hypoalbuminemia ; albumin
RV ; pulmonary embolism
bundle branch block ; electrical activation ; dyssynchronous heart failure ;HF ; electromechanical ; heart
heart failure ;heart team ; cardiologists ; cardiovascular surgeons
Baroreflex sensitivity ; heart rate variability ;HRv ; CHF-inv ; sham-inv ; renal DNx
bisphosphonates ; alendronate ; etidronate ; heart failure ; compliance
nurse ; cognitive impairment ; hospitalization ; heart failure
HF-ACtion ;HF ; ejection fraction ; exercise
herbal medicine ; ghm ; dilated cardiomyopathy ; dm ; heart failure
serum resistin ; anthracycline-containing chemotherapy ; cardiotoxicity
sst2 ; high-dose ; cardiovascular event rate
Rad Q66p ; cardiomyopathy ; mechanism
ventricular ; fiber ; sheet orientation
baseline ; SDQT-to-SDr ratio ; HFVT ; HFVT ; hNorm
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; left ventricular ejection
electrical stimulation ; peripheral muscles ; endothelial function ; emotional ; heart failure ; left ventricular ejection fraction
baseline ; cardiac transplant ; ecb
diastolic dysfunction ; pathophysiology ;HFpEF ; non-diastolic abnormalities ; cardiovascular function
emd ; dyssynchronous HF
hypertension ; hff ; DASh ; svh ;target sodium
doxorubicin-induced cardiotoxicity ; Hum-Retn ; resistin ; retn
arrhythmia substrate ;AMI ; HR ; arrhythmia events
dietary ; heart failure ;HF ; evidence ; HF
HF ;AMI ; pna ; mortality
hypertension ; hg ; diabetes mellitus ; systolic ; diastolic murmurs
tpse ; PASp relationship ; hff ; HFpEF ; resolution
epigenetic ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac
NT-probNP levels ; all-cause mortality ; acute HF
haematopoetic cell transplantation ; ght ; congestive heart failure ;CHf ; pre-hCT ; anthracyclies
cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; cumulative administration ; doxorubicin
inhibition ; antagomir ; spontaneous cardiac dysfunction ; murine myocardium ; heart failure
carvedilol ; β-blocker ; β-blocker ; metoprolol ; thromboembolic events ; heart failure
cox regression models ; propensity score ; oral glucocorticoid ; HF ; loop diuretics
preoperative albumin ; mortality ; lVAD ;hazard ratio
dyssynchronous HF ; electromechanical delay ;EMd ; myocyte depolarization ; myofiber
Beta blockers ; readmissions ; heart failure ; ejection fraction ;HFrEF ; heart rate ;HR
bleeding ; driveline ; infection ; gastrointestinal bleeding ; stroke ; Rankin Score
Dialysis ; HF
functional electrical stimulation ; fes ; exercise capacity ; emotional stress ; endothelial function ; heart failure ; systolic function
ejection ; cardiac index ; inotropes ; inotrope-dependent ; medical ; transplant
systolic heart failure ; QRs ; cRT ; rate of death ; hospitalization ; heart failure
lipoprotein ; hdl ; endothelial-protective ; endothelial cell ; nitric oxide
fluo-cAMP binding ; phosphomimic ; ser77 ; ser83 ; mutant ; RIα proteins ; kvd ; wt RIα
outcome ratings ; admission to discharge ; heart failure ;HF ; Nursing outcomes classification ;noc
insulin resistance ; type 2 diabetes ; insulin receptor substrates ; irs1 ; irs2 ; insulin-signaling ; cellular metabolism
dgs ; non-ischemic ; ischemic heart failure ; heart failure
hh ; saxagliptin ; sitagliptin ; antihyperglycemic agents
QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ;RAF
heart magnetic resonance imaging ; chelation choices ; compliance ; heart failure ; arrhythmias
EDs ; heart failure ; ED ; readmissions ; ED
anticoagulation ; rate control ; cardiovascular complications ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
nitroxyl ; hno ; Angeli ; inotropic ; lusitropic ; vasodilator effects ; cAMP
Gene expression ; Bax ; bcl-2 ; mRNA expression ; heart failure ; bcl-2 ;Bax
cps ; eacm ; vgf2
ejection fraction ; pre-PD ; NYha ; class IIIb ; right ventricular dysfunction
evidence ; continuous-flow lVADs ;HeartMate ;HM II ; HeartWare ; bt ; dt
heart disease ; HF
cRT-d ; icc ; cRT-d ; IEs
Frailty ; physical ; activity ; unintentional weight loss
transplant ; PD ;HF ; post-PD
SAF ; liver
biomarker studies ; biomarker-guided clinical trial
report ; right atrial myxoma ; embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
right heart failure ; refractory cardiogenic shock ; heart ; corporeal membrane oxygenation ; ecm ; cp ;ICU
cardiac VEGF expression ; Akt ; endothelial NO synthase activation ; hearts
heart failure ; left ventricular systolic dysfunction ; BB
baseline ; post-DASh ; srd ; brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular ; echocardiographic
cardiac insulin-resistance ; post-aac ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
Gene expression profile ; gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure
exercise-induced PASp ; right ventricular contractile reserve ; exercise-induced PASp
Gene expression profiling ; cultured cardiomyocytes ; jq1 ; induction ; phenylephrine-induced genes
psychosocial factors ; exercise ; Heart Failure ; Heart Failure ; exercise training ;HF-ACtion
ST2 ; outcomes ; HF
baseline ; blinded core
cardiovascular diseases ; heart failure ;HF ; HF
bem ; bem ; inhospital mortality
mortality ; mortality
DASh ; diet scores ; mortality ;HF ; diet scores
keletal muscle mass ; relative appendicular lean mass index ; z-score
cnca ; heart failure ; glomerular filtration rate ; reNAStur
intubation
black race ; HF ; exercise performance ; HF ; exercise
hearts ; nacleolin ; chamber patterning ; cardiac looping ; myocyte differentiation
wasting of fat ; lean mass ; fat loss ; enhanced catabolism ; adipose tissue ;HF
drugs ; heart failure ; biomedical
hf ; exercise ; respiratory gas ; baseline
hearts ;TTA ; tgtMena ; mice ; heart mass ; transgenic mice
raloxifene ; mechanism of action ; heart failure
coronary angiography ; systolic HF ; etiology
arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ratio ; ees ; ea
heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; emotional ; endothelial function ; hpEF
bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
evidence ;HF ; ejection fraction ;HFrEF ; HF ; ejection fraction ;HFpEF
Cells ; angiotensin II ; angII ; hypoxia ; activators ; scn5a ; mRNA splicing ; induced ; scn5a
rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device ; rhythm
expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
change ; readmissions ; hospital
contractility ; ventricular-arterial coupling ; ivabradine-treated
power spectral ;LF ;HF ; CHF-inv ; sham-inv ; sham levels ; DNx

cardiac magnetic resonance ; postcontrast ; hff ; postcontrast ; hff
myocardial ; collagen deposition ; titin ; obese ; diabetic zSF1 ; heart failure ; ejection fraction
HF-ACtion ; left ventricular ejection fraction ; New York Heart association ; HF ; exercise
adverse event rates ; acute myocardial infarction ; congestive heart failure ; in-hospital
natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
Macrophages ; cardiomyocytes ; Hum-Retn ; doxorubicin ; hretn ; mRNA ; protein expression
collected ;HF ; immunoreactive NT-probNP ; NT-probNP
EH ;HFpEF ; HF ; hf ; therapy
withdrawal ; sympathetic tone ; parasympathetic tone ; heart rate ; metoprolol ; atropine
fm ; nps ; baseline ; FM ; fm ;NPs ; adiponectin
lVADs ; HeartMate ; Thoratec Corp ; Pleasanton ; Calif ; hVAD ; HeartWare intl ; intl ; Framingham ; mass
beat-to-beat QT interval ; eCGs ; baseline ; esmolol ; isoprenaline ; atropine infusion
rule ; CAD ; angiography ; systolic HF ; cost
frailty ; health ; abshort physical performance Battery ; hawt Battery ; Gill index ; HF
HF ; QRs ; LVEF ; cRT ; reverse remodeling ; LV ; systolic dysfunction
HF ; t2d ; ERC ; treadmill ;VO2max ; oxygen consumption ; Skm ; biopsies
percutaneous revascularization ; angioplasty ; stenting
gastrointestinal bleeding ; incessant ventricular tachycardia storm ; terminal heart failure
load-corrected chronotropic response ; heart rate ; exercise ; baseline ; follow-up tests ; heart rate ; exercise
cardiac tissue ; TAC ; jq1 ; BET inhibition ; pathological cardiac gene expression
epigenetic ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; pathological gene expression ; HF
binomial regression models ; health
death ;heart failure ; noncardiac ; cardiac transplant
Peak oxygen consumption ;VO2max ; HR
admission ; NT-probNP ; ED ; acute HF
conditional gene-targeted hand ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; induction
Systolic blood pressure ; left ventricular ;LV ; hypertrophy
RV ; lVAD ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
PF ; New York Heart association ; SAF ; PF
HF ;AMI ; odds ratio
EDs ; heart failure ; ED
report ; conditions ; turkey
western Australian ; administrative ; health ; HF ;AMI
physicians ; mortality ; physicians

outcome measures ; treatment ;HF
free-breathing pulse sequence ; myocardial t1 ; swine model ; tachycardia-induced heart failure
frail ; Gill index ;HF

Chronic β-AR ; catecholamine infusions ; pde2 ; expression ; cAMP hydrolytic activity ; blunted cardiac β-AR responsiveness
Xanthine oxidase ;XO ; left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula ; acf
zf1 groups ; heart failure ; ejection fraction ; lung weight ; left ventricular ejection fraction ; left ventricular
chronic pAH ; RV ; pharmacologic therapies ; RV failure management ; pAH
Chronic heart failure ; ghf ; disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
heart failure ; ejection fraction ;HFpEF ; health
inhibitor ; jq1 ; bets ; chromatin ; downstream ; signalling ; RNA polymerase II ;pol II
report ; ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
RA ; methotrexate ; tnf antagonist ; non-biological disease ; antirheumatic drug ; nabDMARD
cyclic adenosine monophosphate ; cAMP ; cyclic guanosine monophosphate ; cgm ; hearts
cox proportional hazards regression ; ie ; hospitalization ; acute coronary syndromes ; coronary interventions
miRNAs ; rnas ; expression ; binding ; messenger ; rna
catheter ablation ; atrial fibrillation ;AF ; heart failure ; ejection fraction ; hff
HFpEF ; ivabradine
healthcare ; care management ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
outcome measures ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pna
pathophysiology ; HF ; medical ; pathophysiologic state
nps ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
Cardiac c-Kit ; cardiac explant-derived cells ; cardiac functions ; myocardial infarction
sphingosine-1-phosphate receptor ; s1p ; β1-adrenergic receptor ;β1AR ; g-protein-coupled receptors ; heart
EF ;LCx ; LAD ; stenting ; infarcted left ventricle ; LCx ; LAD
microRNAs ; expression ; bhh ; transcription factor ; hand2 ; postnatal mammalian myocardium ; embryonic gene ; heart failure
BET ; bromodomain proteins ; bets ; acetyl-lysine reader proteins ; HF ; pathogenesis ; HF
cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
hART ; New York Heart association ;NYha ; hospitalized ; HF ; self-management counseling ; outcome of death ; HF
mVA ; surgical ring implantation ; leaflet ; leaflet ; edge-to-edge anastomosis
compliance ;LV ; end-diastolic volume ; LV ; end-diastolic pressure ; hg β coefficient
septal ; PCp
Rad Q66p ; inhibitory ; Rad ; cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
atrial fibrillation ; carvedilol ; metoprolol
ERC ; DAPc ; sarcomeric ; markers ; Skm ; myofibre
gs ; LVf ; cv ; echocardiographic systolic ; af
prescribed ; cp ;pharmacological
nordic walking ; standard cardiac rehabilitation care ; functional capacity ; heart failure
Bradycardia induced ; intravenous metoprolol ; cardiac sympathetic tone ; CHF-inv ; rabbits ; sham-inv ; CHF-DNx
blood transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
evidence ; erythropoiesis-stimulating agent therapy ; venous thromboembolism
voltage-gated ; plateau phase ; ventricular ; excitation-contraction ; coupling ; myocardium
heart failure ;HF ; tumor necrosis factor ; tf ; tnf ; HF
peak oxygen uptake ; metabolic exercise ; cardiac ; kidney index ; composite HF
genetic ; CHF ; predictive model ; auc ; genetic ;AUc
chronic myocardial ischemia ; stent ; polytetrafluoroethylene tube
black race ; mortality ;hospitalization ;hazard ratio ; cardiovascular mortality ;HF
Centers for Medicare and Medicaid services ; cvm ; hospital ; quality of care outcomes ; publicly ; mortality ; readmission rates ; penalties
β-blockade ; disease progression ; cAMP-dependent protein kinase ; pKA ; β-adrenergic receptor activation
foundation ; right heart ; circulatory failure ; mechanisms of disease ; right heart
HF
Grading of evaluation ;GRADe ; methodology
aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; systolic dysfunction
AT1 receptors ; neprilysin blocks ; renin-angiotensin-aldosteron ;RAS ; axis ; natural vasodilatory ; diuretic ; natriuretic peptides
bp ; glomerular filtration rate ; hypertension ; transmitral ; e-wave ;early diastolic mitral annular velocity
ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; ejection fraction ; hpf
medication
HR variability ;turbulence ; HR variability ; turbulence ; cardiac
low-dose dopamine ; low-dose nesiritide ; renal function ; acute heart failure ; renal dysfunction
hm II ; HeartWare ; economic ;HM II
death ; glomerular filtration rate ;odds ratio
creatinine ;hazard ratio ; post-transplant mortality
lVAD ; surgery ; albumin levels ; hypoalbuminemia
pathophysiological
cox proportional hazard ; follow-up ; physician ; outcome ; death
rule ; CAD ; stenosis ; CAD ; anterior descending artery
outcomes ; heart failure ; acute myocardial infarction ; acute myocardial infarction ; western Australia
Randomized aldactone evaluation study ; chronic advanced heart failure ; aldosterone antagonist ; spironolactone
combination ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular dilatation
hff ; sodium-restricted DASh ; diet ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
signal transduction cascade ; transcription factors ; pathological ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin
CHF ; hCT ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
HDl ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-βII-Ser ; p70s6k-Ser
cRT ; HF ;hazard ratio ; LVf
heart failure ; myocardial collagen ; heart failure
administrative ; Alberta ; heart failure
mouse ; ventricular myocytes ; sarcomere ; transient
ss ; hm ; ss
PASp
lVAD therapy ; transplantation eligibility ; bt ; dt ; medical therapy
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1p ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1p1 ; cardiac gene therapy
radial artery tonometry ; admission ; PH ;ICU
cardiomyocytes ; pde2 ; activity ; cgm ; nitric oxide donors ; pde2 inhibition ; β-AR
ejection fraction ; natriuretic peptide levels ; heart failure ; inhospital outcomes ; guideline-Heart Failure Registry
Breast cancer ; Medicare coverage ; breast cancer ; chemotherapy ;EER-Medicare ; Texas Cancer Registry-Medicare
eRK1/2 ; signalling ; signalosome ; scaffold protein drives ; kinases ; sequential phosphorylation
magnetically levitated ; centrifugal-flow chronic lVAS
l-dco ; cardiac ; irr1 ; irr2 ; heart failure ; cardiac energy metabolism ; gene expression ; p38α ; mitogen-activated protein kinase
heart failure
hospitals ; heart failure ;HF ; conditions ; acute myocardial infarction ; pneumonia ; conditions
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MAD-cRT ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
Caloric restriction ; aerobic exercise training ; Peak oxygen consumption ; Heart Failure ; ejection Fraction
ventricular assist devices ; lVADs ; heart failure ;bridge to transplantation ; bem ; transplant-ineligible ; dt
right ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; right ventricular ejection fraction
haemodynamic ; heart failure ; ejection
relative risk ; rr ; heart failure ; bisphophonates ; rr ; hazard ratio ;HR
acp ; red blood cell transfusion ;trigger hemoglobin threshold ; hemoglobin levels ; coronary heart disease
Medicare ; fee-for-service ; Centers for Medicare ; Medicaid services ; propensity-score
acute heart failure ; renal dysfunction ; low-dose dopamine ; low-dose nesiritide ; renal function ; diuretic therapy
Rhythm control therapy ; af ; sinus rhythm ; rhythm control
kv ; New York Heart association ; HFpEF ; HF
nicorandil ; doxorubicin-induced heart failure ; hemodynamic perturbations ; mitochondrial dysfunction ; antitumor activity
physician ; guideline ; heart failure ; Clinical practice guideline ; cg ; outcomes ; heart failure ;HF
HF ; body composition ; skinfold ; dual-energy x-ray absorptiometry ; echocardiography ; blood testing
cardiac insulin-resistance ; mitochondrial oxidative metabolism ; metabolic changes ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
economic ; Heart failure ; cost-efficient ; disease management ; heart failure
Rad ; rg ; rem ; Rem2 ; Rad ; Gem ;Kir ; monomeric g proteins ; ventricular action potential ; coupling ; gain ; cardiac l-type channel activity
breathing control ; cardiac arrest ; advantage ; pulseless ventricular fibrillation ;PVf ; cardioverter-defibrillator device
combination ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular ;LV
pathophysiology ; heart failure ; ejection fraction ; hf ; myocardial extracellular matrix accumulation
cox model ; PASp ; exercise ; peak o2 per kilogram ;hazard ratio ; peak o2 per kilogram ; PASp
Oral glucocorticoids ; HF
HFPSI ; medical ; hospitalization ; HF ; outpatients ; HF
HR ; ivabradine ; ea ; TAC
guidelines-heart Failure ; HF
change ; peak VO2 ; change ; lean body mass ; change ; thigh muscle ;intermuscular fat ratio
testosterone ; exercise ; health outcomes ; CHF ; testosterone
ethnic groups ; CHm ; adjunctive treatment ; dm ; heart failure
carvedilol ; metoprolol ;hazard ratio
acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ;HF ; myocardial infarction
re-hospitalization ; admissions
financial ; cardiac arrest ; cardiopulmonary resuscitation ; cvp ; posterior wall infarction ; cardiac
heart failure ;HF ; ejection fraction ;rEF ; renin-angiotensin system ;RAS ; β-blockers ; readmissions
uPR ; sn5a ; ventricular systolic HF ; induced pluripotent stem cell-derived cardiomyocytes ;hipsc-CMs
type 2 diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; sulfonylureas ; insulin
evidence ; acp ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
hyperkalemia ; mineralocortic receptor antagonists ; mineralocortic receptor antagonists ; heart failure ;HF
pde ; pde2 ; cgm ; cAMP hydrolysis ; cross talk ; cgm ; cAMP
mitochondrial-targeted antioxidant ; Szeto-Schiller ; ss20 ; cardiac function ; proteomic remodeling
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-mig ; β-blocker
tpse ;longitudinal RV fiber shortening ; PASp ;force ; RV ; length-force relationship
urine ; decongestion ; change ; serum cystatin c ; enrollment ;renal function
brain natriuretic peptide ; bem ; pg ; pg ; bNP ; bNP ; pg
LVEF ; reverse ; HF ;hazard ratio
stockholm ; web-system for evidence-based care ; Heart disease ; Recommended Therapies ; primary isolated cab ; sweden
probNP ;NT-probNP ; proanp ;MR-proanp ; CHF ; bem
hazard ratios ; HF
carvedilol ; wilebrand factor ; metoprolol ; β-adrenergic receptor haplotype
HDl ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Ser ; HDl
HF ; HF ; HF ; change ; HF ; MI
ctnt ; NT-probNP ; aRIC HF model ; acs ; NRIs
cardiovascular events ; baseline ; sst2 ; BB ; metoprolol succinate
Medicare ; acute care hospital ;HF ; AMI ; pna
cochrane effective practice ; organisation of care taxonomy
heart failure ;HF ; hypertensive heart disease ; hh ; pathophysiology ; hh
coPD ; CHF ; cf ; icc ; kappa coefficients
left ventricular longitudinal systolic strain ; grs ; left ventricular mechanics ; adverse cardiovascular ;CV ; atrial fibrillation ;AF
implantable cardioverter-defibrillator deactivation ; distressing ; implantable cardioverter-defibrator shocks
heart failure ; myocardial function ; dilated poorly contracting ventricles ; aetiologies
implantable cardioverter-defibrillator deactivation ; change ; treatment
stable heart failure ; left ventricular ejection ; aerobic ; training ; dynamic resistance
mouse ; Rad Q65p ; murine ; Rad ; Q66p ; currents ; cav1.2 ; cav1.3 ; wild-type Rad
cRT ; hazard ratio
cRF distribution ; hazard ratios ; unfit ; overweight ; body mass index ; obese
left ventricular ejection fraction ; egf
cost ; rhythm-control ; rate-control
prescribing ; medications ; medical records
ethically ; religious beliefs ; decisions
Medicare ; Patient safety monitoring system ; msm ; adverse event ; acute myocardial infarction ; congestive heart failure ; pneumonia ; conditions ; surgery
sarcoplasmic reticular ;SR ; protein ; SR ; pump ; phospholamban ; infarcted hearts ; metoprolol
HFPSI ; blood urea nitrogen ; natriuretic peptide ; New York Heart association ; diabetes ; atrial fibrillation ;flutter
Time up and go ; tgf ; chronic obstructive pulmonary disease ; coPD ; chronic heart failure ;CHf ; chronic renal failure ;CRf
RM ; home telemonitoring ; implanted monitoring devices ; medical ; ss ; contact ; hh
heart failure ;HF ; b-type natriuretic peptide ; bem ; ejection fraction ;EF ; HF ; sex
gs ; left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; cv
hawt ; LVEF ; LVEF ; long-term mortality
exercise ; intramuscular testosterone ; chronic heart failure ; ghf ; testosterone ; health outcomes
cox regression ; beta-blockers ; beta-blockers ; antitachycardia pacing ; tp ; shock therapy
exercise ; Minnesota ; quality of life ; exercise
congestive heart failure ; ed
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers ; heart failure ; ejection fraction
rats ; hearts ; excised ; caspase-3 ; activity ; phosphocreatine ; adenine nucleotides ; cytochrome ; bcl2 ; Bax ; caspase ; expression
right ventricular ; gene expressions ; Bax ; bcl-2 ; Caspase-3 ; RTq-PCr ; interventricular septum biopsies ; beagle dogs ; heart failure
hypertension ; diet ;DASh ; srd ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hff
physical ; implantable defibrillators ; circulatory ; transplantation ; heart failure
cd34-vegFR2 ; cells ; functional capacity ; cd34-vegFR2 ; cells ; peak VO2
arginine vasopressin ; aVP ; physiologic ; CHF ; aVP ; vasopressin receptor antagonist therapy ; CHF
treatment ; heart failure ; ejection fraction
aerobic ; resistance training ; exercise capacity ; muscle strength ; cardiac ;NT-ProbNP ; inflammatory ; il6 ; hsCRp
reversibility ; heart failure ; myocardial infarction ; m ; β-adrenoceptor blockade ; infarcted rats ; metoprolol
fatigue ; muscle strips ; kv-KI ; treatment ; titin ; titin ; extracellular matrix ; fpassive
CHF ; anthracycline exposure ; stem cell source ;allogeneic
case-fatality rate ; HF ; HF ; case-fatality rate
readmission ; all-cause readmission ; acr ; potential Preventable Readmission ; pp ; Centers for Medicare ; Medicaid ; 30-day readmission ; cvm
metoprolol ; carvedilol ; sympathetic activity ; von Willebrand factor ; arg16 ; grln27 ; lendi27
acute HF ; RELAx-aHF ; ASTRONAUT ; PRONTO
HF ; international classification of Diseases ; Ninth revision ; Clinical ; principal
pulmonary capillary wedge pressure ; hg ; baseline ; hg ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
Rad ; Q65p ; gating ; movement ; wild-type Rad ; Q65p ; l-type channel ; inhibition ; Rg proteins
SS20 ; heart failure ; proteomics ; actin cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
aortic insufficient ;AI ; mechanical circulatory ; continuous flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
administration ; pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; HF
follow-up
heart failure ; refractory ; terminal heart failure
heart failure ; university of connecticut ; health Center
New York ; Heart association ;NYha ; Heart Failure ; eplerenone ; standard Heart Failure Medicines ;EMPs-HF
echocardiograms ; left ventricular base ; midpapillary ; baseline ; IVc occlusion ; BiVP ; STE ; twist ; basal rotations
evidence ; drugs ; raas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic ; calcium-sensitizing agents ; antagonists ; endothelin ; vasopressin ; adenosine
HF induced ; phenylephrine ; haemodynamic stress ; surgical method ; transverse aortic constriction ;TAC ; jq1 ; pathological ; cardiac hypertrophy
Muscle aerobic capacity ; postexercise ; phosphocreatine resynthesis ; Fontan
i-mig ; cardiac washout ; carvedilol ; metoprolol ; β-adrenergic receptor haplotype
treatment ; acute myocardial infarction ;AMI ; heart failure ;HF ;AMI
h-dco ; ventricular mass ; cardiac apoptosis ; fibrosis ; Akt ; forkhead box ; o-1 ; cardiac metabolic gene expression ; ATP
bottleneck stent ; anterior descending ; LAD ; proximal circumflex artery ;LCx ; LCx ; LAD
postmarketing ; hospitalized heart failure ; hHF ; dipeptidyl peptidase-4 ; dp-4 ; inhibitors ; antihyperglycemic agents
cox modeling ; Heart Failure Patient Severity index ;HFPSI ; university of Michigan ; HF ; UM ; outcome
pde2 ; overexpression ; cardiomyocytes ; cAMP ; ca2 ; inotropic effect ; β-AR ; basal contractility
inappropriate ATP ; inappropriate shock therapy
Cardiac resynchronization therapy ; cvt ; dialysis-dependent ; heart failure ;HF ; ct ; dialysis
cardiorespiratory fitness ; cvf ; body mass index ; heart failure ; HF ; cardiovascular risk factors ; HF mortality
eplerenone ; hyperkalemia ; renal function ; emPHAs-HF ; eplerenone ; Mild Patients Hospitalization ; SurvIval study ; Heart Failure
Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHf ; left ventricular ;LV
neonatal rat ; ventricular cardiomyocytes ; chronic insulin exposure ; irr1 ; irr2 ; insulin ; p38 ; fundamental mechanism of cardiac dysfunction ; insulin resistance ; type 2 diabetes
echocardiograms ; left ventricular midpapillary ; atrioventricular delay ; vd ; interventricular delay ; vd ; STE ; radial ;RS
New York Heart association ; mwh ; ejection fractions ; chronic stable guideline-directed medical therapy ; ghm ; united states ; Canada ; europe
lb ; QRs ; hazard ratio ; primary outcome ; QRs ; hazard ratio
dyssynchronous HF ; myofiber ; velocity ; early-activated septum ; myofiber ; stretch rate
shotgun proteomics ; proteomics ; transverse aortic constriction ;TAC ; heart failure
CHF ; transforming ; growth factor-β ; tgf-β ; epithelial ; mesenchymal transition markers ; expression ; pluripotency markers ; shams
pKA ; change ; regulatory ;RIiα ; catalytic ; expression ; rIIα ; ser96) ; phosphorylation ; HF
hf ; left ventricular ejection fraction ; HFpEF ; left ventricular ejection fraction ; RAS- ; β-blocker ; dose changes ; HF
g-protein-coupled receptors ; reciprocal regulation ; mouse hearts ; β-adrenergic receptor ; postischemic heart failure
concentric remodeling ;CR ; concentric hypertrophy ;CH ; left ventricular ;LV ; heart failure ; ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
exercise ; exercise ; diet
RV ;hazard ratio ; cachexia ;hazard ratio
resting HR ; follow-up ; baseline ; VO2max ; HR
tg-β inhibition ; c-Kit+ cell ; cardiac progenitor function ; cell expansion
NT-ProbNP ; inflammatory biomarkers ; hsCRp ; il6) ; hsCRp
BETs ; neurohormonally induced heart disease ; nanomolar doses ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
BAT ; exercise capacity ; N-terminal pro-brain natriuretic peptide ; burden of heart failure ; GDm-treated NYHA
p70s6k ; PKc-βII ; HDl ; mwha-IIIb ; malondialdehyde bound ; HDl ; mwha-IIIb
MLh ; exercise ; diet ; exercise ; diet
nonpace ; non-DNx ; ham-innervated ; sham-inv
hawt Battery ; HF ; health ; ABC HF model ; death
ejection fraction ; frail ; biological ; death ; frailty ; deficit index ; death
hemoglobin ; ghg ; HRQol ; training-induced changes ; HRQol ; Heart Failure ; exercise training ;HF-ACtion
atrial Fibrillation ; congestive Heart Failure ; health care ; expenditures ; Québec ; rhythm ; rate-control ; treatment ; cost
heart failure ; compliance ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
report ; calcineurin ;nfat ; expression ; basic helix-loop-helix ; bh ; transcription factor ; dHAND ; hand ; mouse ; myocardium
exercise ; PSs ; bems ; exercise ; PSs ; bems
NT-probNP ; admission ; pg
prognostic power ; HR ; fractal scaling
diastolic function ; diastolic filling ; relaxation ;viscoelastic ; doppler mitral inflow velocity ; e-wave
heart failure ;HF ; ventricular tachycardia ;HF ; HF ; VT ;HF ; structurally normal hearts ; hNorm
gs ; cox model ; heart failure ; hypertension ; diabetes ; stroke score ; glomerular filtration rate ; LVEF ; cv
VAD ; ventricular assist device ; ecmo ; extracorporeal membrane oxygenation membrane ; ecmo ; VAD
ischemic events ;IEs ; ischemic cardiomyopathy ; icc ; cardiac resynchronization therapy ; defibrillator ; cv-d
cost-effective ; heart failure disease ; evidence-based treatments ; health care system
heart failure ; mouse ; murine ; transgenic ; Retn gene ; hum-retn mice ; basal ; inflammation-stimulated
angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; β-blockers
TTA ; tgtMena ; cardiac injury ; ejection fraction ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ; implantable cardioverter defibrillator-cRT ; primary end point ; heart failure
heart failure ; italy ; confirmatory factor ; caf ;SCHf ; self-Care ; self-Care management ; self-Care Confidence
mwt ; hawt ; HFpEF ; hff ; prescribed ; therapy ;HFpEF ; HF
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; ischemic cardiomyopathy
Raf-MEK1/2- erk1/2 ; scaffold proteins ; cardiac remodelling
CHF ; testosterone levels ; exercise ; testosterone
ms ; dynamic ; LV dilatation ; treatment for heart failure ; HF ; ms ; HF ; MR ; prolapse ; mitral valve
New York Heart association ; ccq ; Spearman ; aNOVA ; HF ; hpEF
angiotensin converting enzyme inhibitor ; angion-receptor blockers ; β-blockers ; heart failure ; medical records
c57b ; ang II infusion ; ang II infusion ; uninephrectomy ; ang II infusion ; salt loading ; ang II infusion ; uninephrectomy ; salt loading
early transmitral blood flow velocity ; doppler ; early diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcp ; systolic heart failure ;HF
systolic indices ;LV ; ejection fraction ; strain ; strain rate ; systole ; diastolic indices ; strain rate ; diastole ; early transmitral flow ; sinus rhythm
peak VO2 ; exercise ; body mass ; diet ; body mass
hazard ratios ; early-onset HF ; late-onset HF
AMI ; hospital ; hospital
mass spectrometry ; circulating ; NT-probNP ; physiological proteolysis ; pro2-leu3 ; lendi3-gly4 ; pro6-gly7
ctnt ; NT-probNP ; report ; ctnt ; NT-probNP ; HF prediction model
HFpEF ; New York Heart association ; ejection fraction ; fes
left ventricular ;LV ; systolic pressure ; ejection fraction ; cardiac output ; LV ; end-diastolic pressure ; MI ; metoprolol
baroreflex activity Therapy ; Heart Failure ; ejection Fraction ; carotid baroreflex activation therapy ;BAT ; advanced heart failure ;HF
outcome ;hazard ratio
LA ;HF ; raised blood glucose levels ; obesity ; tobacco ; aging ; systemic hypertension ;SH ; rheumatic fever ; chagas ; disease ; LA
cf ; overweight ; obese body mass index
kvp ;HFpEF ;log ; EF
baseline ; egFR ; egFR ; uncontrolled hypertension ; diuretics ; erd
myocardial phosphodiesterase-2 ; pde2 ; heart failure ; HF ; pde2 ; beta-adrenergic receptor ;β-AR ; cardiomyocytes
heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibretor device ; carvedilol ; ATP ; shock therapy ; metoprolol
ERC ; epicatechin-rich cocoa ; Skm ; mitochondrial ;Taub ; Ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; Maisel ; Henry
urgent readmission ; physician
Mena ; TTA ; tgtMena ; TAC ; surgery ; Mena levels ; cardiac hypertrophy ; TTA ; tgtMena ; post-TAC ; cardiac functional
echocardiography ; LV ; end-diastolic volume ; MR ; mitral valve opening ; mVA ; pressure gradient
PD ; diuretic refractory ; HF ; PDrelated
ATP production rates ; post-aac ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium ; hyperkalemia ; medication
New York ; Heart association ; heart failure ; HF ; ventricular ejection fraction ; permanent periodic breathing ; PB ; report
bottleneck stent ; LAD ; LCx ; reversible myocardial ischemia ;open stent ; ischemic heart failure ; stent
potassium ; spironolactone ; as ; as
obese ; body mass index ; hff
proangiogenic ; veg pathway ; injected ; adenoviral vector ; veg receptor ; ad-fraud ; adenovirus ; ad-c
post-LVAD ; aortic valve ; leaflet ; bioprosthetic ; aortic valve replacement ; CF lVAD ; symptomatic ; AI
exercise-induced pulmonary artery systolic pressure ;PASp ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
MEDline ;EMBAse ; healthSTAR ; cinahl ; cochrane Library ; Campbell collaboration ; Joanna Briggs institute ; evidence based practice ; centre for reviews and Dissemination ; evidence based practice
health care systems ; systolic heart failure ; prescribed ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocortic receptor antagons
open chest model ; twist ; RS ; RS synchrony ; STE ; RVpo ; RS synchrony ; biVP
tpse ; PASp ; tpse-to-PASp ratio ; pacse ;PASp ; cox regression ; Kaplan-meier ; tpse ; PASp
cp ; CHF ; exercise ; exercise ; exercise
heart failure ;HF ; mRNA splicing ; voltage-gated cardiac ; na-subunit ; sn5a ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; cellular ; heart failure ; anthracycline ; childhood malignant disease
economic ; Patient management Interventions ; Heart Failure ; cost-efficient model ; evidence-based medications ; costs
natriuretic peptides ;NPs ; na-terminal pro-b-type NP ; acute heart failure ; Emergency department ; ed ; acute dyspnea
peak oxygen consumption ; peak VO2 ;VEN ; vco2 slope ; exercise ; oscillatory ventilation ; eOV ; end-tidal co2 ;PETco2 ; cardiopulmonary exercise testing
denmark ; bisphosphonates ; raloxifene
hypertension ; LV dilatation ; LV dysfunction ; ms ; mitral valve ; organic lesion ; systolic ; diastolic tethering ; functional etiology ; ms
tolvaptan ; hyponatremia ; united states ; japan ; congestive heart failure ; diuretic therapy ; serum sodium levels ; systolic function
left ventricle ; echocardiographic ; baseline ; echocardiography ; cr ; follow-up echocardiograms
platelet-activating factor ; pif ; metabolic enzymes ; heart failure ; hf ; bem-matched
acute care surgery ; acs ; oHT ; transplantation ; medical therapy ;MT ; intravenous inotropes ; ventricular assist devices ;VADs
hpf ; ivabradine ; exercise capacity ; left ventricular filling pressure ; exercise ; peak early diastolic mitral flow velocity ; early diastolic mitral annular velocity
renin-angiotensin-aldosterone system ;RAas ; hf ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; evidence ; hpEF
admission ; VET ; tonometric indices
heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers ; β-blockers
cardiac ; β-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump function ; reverse ; cardiac remodeling ; plasma catecholamines
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers
SS31 ; congestive heart failure phenotypes ; mitochondrial damage induced ; TAC ; mitochondrial proteome ; mitochondrial ; nonmitochondrial protein changes
myofibrillar ; ATPase ; mRNA levels ; phospholamban ; α-myosin heavy chain ; mRNA ; β-myosin heavy chain ; metoprolol
HDl ;HDl ; CHF-NYHA-III ;HDl ;NYHA-III ; CHF-NYHA-II ;HDl
anesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
md ; md ; md
baseline ; heart failure ; administration ; contrast agent ; administration
etiologies ; HF ; LA ; idiopathic dilated cardiomyopathy ; ischemic ; SH ; valvular ; alcohol
ST2 levels ; functional capacity ; HF ; Heart Failure ; exercise training ;HF-ACtion ; exercise training ; HF
report ; cardiopulmonary exercise testing ; exercise rehabilitation ; chronic heart failure ; exercise rehabilitation ; chronic heart failure ; ghf ; Cardiopactary exercise testing ; cvp ; exercise rehabilitation ; china
AA ; ischemic HF pathogenesis ; NYHA ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
HF-action ; exercise training ; HF ; left ventricular ejection fractions ; HRQol ; Kansas City ; Cardiomyopathy Questionnaire ; kv ; baseline
cr ; systolic dysfunction ; resynchronization reVErses remodeling ; Systolic left v entricular dysfunction ; reVERSe ; left ventricular ;LV ; ejection fraction ;LVEF
glomerular filtration rate ; egf ; diabetes ; total cholesterol ; lDL-cholesterol ; cnca ; gdp
echocardiography ; LV ; end-diastolic ; end-diastolic pressure ;wall stress ; lung ; aCF ; sham group
aUC ; aUC
spironolactone ; hospitalization ; adjusted hazard ratio ; death
cardiac procedures ; cardioversions ; costs ; antiarrhythmic drugs
diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone ; post myocardial infarction ; Heart failure Efficacy ; survival study ; erus ; post-myocardial infarction ; heart failure ; mortality ; hospitalizations ; aldosterone antagonist ; eplerenone
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MAD-pact ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
heart failure-related mortality ; sudden death
DASh ; srd ; brachial systolic pressure ; central end-systolic pressure ; hg
HF ; obese ; body mass index ; black ethnicity ; idiopathic-dilated cardiomyopathy
HF ; LVEF ; Heart Failure Survey ; israel
world health organization ; idiopathic dilated cardiomyopathy ; coronary angiography
european society of Cardiology ; hff ; heart failure ; LV ejection ; left ventricle ; evidence ; diastolic dysfunction ;impaired LV relaxation ; LV ; diastolic stiffness ; LV filling pressures
β1ARs ; s1PR1s ; myocyte ; cAMP production ; report ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
PAf-cp ; PAf ; lyso-PAf-AT ; PAf-AH ; lp-PLA2
heart failure ; ejection fraction ; standard cardiac rehabilitation care ; nordic walking ; exercise
dr-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
skeletal muscle mass ; t-score ; sarcopenic range ; muscle ; wasting ; t-score ; wasting ; t-score
exercise ; testosterone ; baseline ; peak oxygen uptake ; Beck depression inventory ; leg strength ; medical ; short-Form quality of life ; exercise
RAS ; β-blocker uptitrations ; HF readmissions ; hf ;hazard ratio ; confidence interval
Heart Failure ; exercise training ;HF-ACtion ; social ; exercise ; social support score ; svs ; barriers to exercise ; bem
ST2 ; hospitalization ;hazard ratio ; cardiovascular death ; HF ; hospitalization ;hazard ratio ; mortality ;hazard ratio ; hazard ratios ; log2
New York Heart association ; cardiopulmonary exercise ; lean mass ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
low-dose dopamine ; low-dose nesiritide ; diuretic therapy ; renal function ; acute heart failure ; renal dysfunction
cRT ; New York Heart association ; heart failure ; left ventricular ejection ; QRs ; echocardiographic evidence ; left ventricular dyssynchrony
left ventricular ;LV ; ejection fraction ; HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; systole ; diastole
acute coronary syndromes ; CAD ; bem ; NT-probNP ; CAD
baseline ; HF ; lyso-PAf-AT ; PAf-cp ; PAf ; PAf-AH ; lp-PLA2
medical ; sternotomy ; aortic valve ; bioprosthetic ; valve replacement ; dacron patch closure ; aortic valve ; transcatheter ; aortic valve ; open surgery ; aortic valve replacement
cutoff value ; natriuretic peptide ;NT-probNP ; acute heart failure ;HF ; emergency department ;ED
cardiac troponin t ; ctnt ; N-terminal natriuretic peptide ;NT-probNP ; incident HF ; HF ; Atherosclerosis risk ; communities ;ARIc
body mass index ; event rate ; fat mass ; fat-free mass index
interquartile ; body mass index ;interquartile ; COPd ; CHF ; cf
reverse remodeling ; ejection fraction ; mortality ;HF ; dialysis
LV ; contractility ; LVEF ; ratio of systolic blood pressure ; end-systolic volume ; hg
echocardiography ; LV ; end-diastolic volume index ; LV ; ejection ; MR ; mitral valve opening ; ms ; mv ; pressure gradient ; fg
renal Optimization strategys evaluation ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration rate
molecular ; bets ; chromatin-mediated signal transduction ; transcription factor networks ; HF ; pathogenesis ; nuclear factor ; activated t cells ; nef ; nuclear factor-κb ;NF-κb ; transcription factor ; gATA4
mortality ; exercise ; cardiovascular events ; myocardial infarction ; congestive heart failure exacerbation ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
cardiovascular mortality ; hazard ratio ; hazard ratio
EO-s ; diabetes ;EO-s ; peak VO2 ; diabetes ;EO-s ; peak VO2
immunoblotting ; fluorescence resonance energy transfer-based ; video edge detection ; epifluorescence microscopy ; ca2 ; myocardial tissues ; isolated cardiomyocytes ; HF
east ; atrial fibrillation ; Stroke prevention Trial ; onset AF ; stroke ; cha2s2VASc ; usual care ; early rhythm control therapy ; outcome assessment
exercise capacity ; peak oxygen consumption ;VO2 ; QOL ; Minnesota Living with Heart Failure ; mhf ; heart failure ; QOL
TAC-indued proteomic alterations ; mitochondrial-targeted peptide ; SS31 ; perturbed mitochondrial function ; upstream signal ; pathway alterations ; TAC ; mitochondrial-targeted peptide drugs ; heart failure
left ventricular ejection fraction ; HF ; left ventricular ejection fraction ; hospital ; physicians ; outpatient ; costs
HF ;HF ; left ventricular ;LV ; ejection fraction ;HFpEF ; echo-doppler ; natriuretic peptide
EDs ; hospitalized ; adjusted odds ratio ; EDs
cardiac transplant ; ect ; diabetes mellitus ; chronic kidney disease ; glomerular filtration rate
hawt Battery ; health ; ab HF ; risk model ; discrimination ; HF
cf ; RMsea ; self-Care maintenance Scale ; cf ; RMsea ; self-Care management Scale ; cf ; RMsea ; self-Care ; Confidence
BAT ; NYha ; functional class ; change
preoperative hypoalbuminemia ; postoperative normalization ; albumin levels ; hypoalbuminemia ; albumin levels ; lVAD
rehospitalization ; acute myocardial infarction ;AMI ; kidney infection ; urinary tract infection ;UTI
heart failure ;HF ; nonischemic cardiomyopathies ;pharmacological ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; ventricular assist devices
SAF ; PF ; catheterization ; central venous pressure ; hg ; sVR ; cardiac
admission ; bp ; EF ; bp ; pg ; borderline ; pg
heart failure ; heart transplantation ;LV assist device ; death ;hazard ratio
LV ; ejection fraction ; velocity ; systolic elastance ; contractile efficiency ; aCF ; aCF ; allopurinol rats ; o2 ; consumption rate ; isolated cardiomyocytes ; extracellular flux analyzer
hawt ; LV ; hypertrophy ;LVh ; relative wall thickness ;RWt ; LVh ; Rwt ;LVh ; Rwt
lCZ696 ; angiotensin receptor ; neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; ejection fraction ; outcomes ; heart failure ; ejection fraction
blood pressure ; mitral valve plasty ; MR ; prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio ring 30 ; edwards lifesciences ; irvine
shuttle walk test ; peak oxygen uptake ; muscular strength ; echocardiographic ; natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ; health-related quality of life ;Minesota ; Heart Failure ; medical
term ; LVEF ; long-term mortality ; LVEF
ies ;Wistar-kyoto ; lean ZSF1 ; obese ; zSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
Kaplan-meier curves ; log-rank testing ; UM ; va-RT
cox regression ; AF ; hypertension ; sinus rhythm ;hazard ratio
HF-ref ; NYha ; functional class ; egf ; potassium ; eplerenone ; hyperkalemia ; wr
body composition ; fm ; fm ; body fat distribution ; dual energy x-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ;CHf ;cc ; CHF ; myocardial infarction-both
baseline ; drug dose ; spironolactone ; end point of death ; hospitalization ; HF ;hazard ratio ; AAs ;hazard ratio
pulmonary arterial hypertension ; chronic thromboembolic pulmonary hypertension ; right ventricular pump ; pulmonary arterial hypertension ; medication ; stress echocardiography ; cardiopulmonary exercise
cardiovascular death ; HF ; bem ; btes ; cardiovascular death ; HF ; exercise ;hazard ratio ; care group ;hazard ratio
CAD ; diabetes ;odds ratio ; electrocardiographic ; bundle branch block ;odds ratio ; nondiabetes ; dyslipidemia ; hypertension ; tobacco ;odds ratio
ED ; ED ; readmission ; EDs
implantable cardioverter-defibrillator deactivation ; decisions ; implantable cardioverter-defibretor deactivation
Cardiac magnetic resonance ;hazard ratio ; atrial area ;hazard ratio ; pulmonary vascular resistance ;hazard ratio ; cardiac events
HF ; systolic ; left ventricular ejection fraction ; HF ; conditions ; New York Heart association ; echocardiographic ; cardiopulmonary exercise
heart failure ; american college of Cardiology ; acc ; american Heart association ; AHA ; New York Heart association ; hawt ; structural heart disease ; heart failure ; physical exertion ; medical
mv ; end-diastolic volume ; end-systolic volume ; mitral filling flow ; mv ; velocity ; mitral filling flow ; wave doppler echocardiography ; MR ; mitral valve plasty
statitistical ; RM ; all-cause mortality ; sts HH ; Cri ; Cri
hawt ; Ann arbor ; Veterans' affairs ; HF ; clinic ; hawt ; HFPSI ; va-RT ; VA ; HFPSI
hf ; diuretics ; mwt ; NYha
surgery ;HF ; postoperative echocardiography ; end-diastolic volume index ; LV ; ejection ; MR ; mitral valve opening ; mitral valve area ; mv ; pressure gradient ; hg
AAs ; spironolactone ; hyperkalemia ;potassium ; hypokalemia ;potassium
LVEF ; LVEF ;hazard ratio ; LVEF ; LVEF
HFpEF ; primary outcome ;odds ratio ; NYha ; walk test ; mwt ; adherence ; prescribed medications
pulmonary arterial systolic pressure ;PASp ; right ventricular ; RV ; tricuspid annular plane systolic excursion ; tlp ; diastole ; end-systole ; heart failure ;HF ; cardiac risk
reverse remodeling ; pre-Cr ; LV ; end-diastolic ; left ventricle ; left atrial area ; right ventricular ; end-diastolic area ; right atrial area ; right ventricular ; change
receiver ; operating characteristic curve ; ac ; PCp ;septal
iRS1 ; irr2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS1 ; irr2 ; heart-specific ; iRS1 ; irr2 ; double-knockout ; h-dco ; liver-specific ; iRS1 ; irr2 ; double-knockout ; l-dco
natriuretic peptide ; natriuretic peptide ; stable coronary artery disease ; b-type natriuretic peptide ; bnp ; nr-terminal fragment ;NT-probp ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
trastuzumab-treated ; coronary artery disease ; hypertension ; trastuzumab administration ; CHF
LVEF ; composite response ; cRT ; cRT OFF ; LV ; systolic volume ; LV
tg-β ; tg-β receptor type ; smad ; small-molecule inhibitors ; c-Kt+ cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker ; nanog ; c-Kt+ cell ; differentiation ; cardiomyocyte
systolic heart failure ; ivabradine ; SHIft ;Systolic Heart failure ; Treatment ; If inhibitor ivabradine Trial ; ivabradine ; echocardiographic
evidence ; liberal transfusion protocols ; mortality rates ; i2 ; mortality rates ; acute coronary syndrome
readmission ; hazard ratio ; physician ; follow-up
Hazard ratios ; tpse ; hg ;hazard ratio ; pip ; New York Heart association ; functional
hek ; embryonic kidney ; β1ar ; s1p1 ; β1ar ; downregulation ; sphingosine-1-phosphate ; s1r1 agonist ; s1r1 ; downregulation ; isoproterenol ; β-adrenergic receptor agonist
baseline ;Kansas City ; Cardiomyopathy ; Minnesota ; Heart Failure ; depressive ; beck depression inventory ; zung ; self-rated depression ; natriuretic peptide ; endothelial function ; flow-mediated dilatation ; ventricular diastolic function
Renal function ; Chronic Kidney Disease Epidemiology
PARADIGm-HF ; chronic heart failure ; systolic dysfunction ; lgf ; NYha ; bn ; primary endpoint ;cardiovascular death ; heart failure ; arn ; lendilpril ; valsartan
hyperkalemia ; African americans ; as ; white ; New York Heart association ; mwh ; HF ; left ventricular dysfunction ; spironolactone ; Randomized aldactone evaluation study ;RALes
cardiovascular ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration rate ; acute kidney injury
diastolic function ; ea ; hg ; ventricular-arterial coupling ; ea
hazard ratios ; disease risk score ; dRS ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
revascularization ; coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; systolic blood pressure ; bundle branch block pattern ; baseline electrocardiogram
biomedical ; biomedical ; treatment ; CHm ; left ventricular ejection fraction ; left ventricular diastolic end diameter ; outcome
outcome assessments ; stable heart failure ; ventricular ejection fraction ; arg16 ; grln27 ; lendi27 ; haplotype ; β2receptor ; equipotent dosages ; carvedilol ; metoprolol
prescription ; angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; interquartile ; β-blockers
Therapy ; ivabradine ; change ; exertional ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity ; exercise capacity ; ivabradine ; peak oxygen uptake
PAf ; biosynthetic enzymes ;lyso-paf ; acetyltransferase ;lyso-paf-AT ; dithiothreitol ; dt ; cdp ; choline ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; pif-cp ; catabolic isoenzymes ; pif-acetylhydrolase ;PAf-AH ; lipoprotein-associated phospholipase a2 ; lp-PLA2 ; leukocytes
ED cases ;hospitalization ; ED ; ED
ivabradine ; baseline ; follow-up ; exercise capacity ; peak oxygen uptake ; exercise-induced ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
health Buddy program ;hazard ratio ;HR ; inpatient admissions ; baseline
hazard ratios ; quartiles ; Mediterranean diet score ; DASh ; diet score
ctnt ; NT-probNP ;laboratory report ; aRIC ; HF ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; HF ; ac ; discrimination improvement ; net reclassification improvement ; nrri
eplerenone ; hyperkalemia ; renal function ; mwf ; emPHAs-HF ; heart failure ; ejection fraction ;HF-ref ; New York Heart association ;NYHA ; glomerular filtration rate ; egf ; serum potassium
baseline ; NYha ; change ; Duke ; activity status index ; Kansas City ; Cardiomyopathy Questionnaire ; walk test distance
low-dose dopamine ; cumulative urine volume ;dopamine ; change ; cystatin c level ;dopamine
low-dose nesiritide ; urine ;nesiritide ; change ; cystatin c level ;nesiritide
nordic walking ; mwt ; physical ; activity ; right grip strength ; depressive symptoms ;Hospital anxiety ; depression Scale
hyperkalemia ; wRF ; diabetes ; egf ; systolic blood pressure ; hg ;potassium ; hyperkalemia ; wRF ; primary outcome ;hospitalization ; HF ; cardiovascular mortality
hawt ratio ; baseline ; glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; New York Heart association ; atrial fibrillation ; congestive HF
peak oxygen uptake ; hazard ratio ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; diet ; renal disease ; sodium
Kansas City ; Cardiomyopathy ; Minnesota ; Heart Failure ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; fes ; natriuretic peptide ; mitral ; wave ratio
CHF ;Odds ratio ; pre-hCT ; chest radiation ; hypertension ; genes coding ; NAD ; h-oxidase ;RAC2 ; hfe ; doxorubicin efflux transporter ; abc2
